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CORRELATION  BETWEEN  PLASMA  FIBRINOGEN  AND  
GLYCOSYLATED  HEMOGLOBIN  IN  TYPE  II  DIABETES  
MELLITUS  PATIENTS 
Background: Type  II  diabetes  mellitus  occurs  due  to  deficient  insulin  
production  in  the  setting  of  insulin  resistance.  In  India,  more  than  62  
million  people  are  diagnosed  as  having  diabetes. The  risk  of  developing  
coronary  artery  disease  is  2-4  fold  high  in   diabetics  and  this  excess  risk  
was  not  fully  explained  by  classical  risk  factors  like  smoking,  
hypertension  and  dyslipidemia. Fibrinogen  in its  high  level  involved  in  all 
stages  of  atherogenesis  and  considered  as  an  important  cardiovascular  risk  
factor. 
Aim  and  objectives:  To  compare  the  plasma  fibrinogen  level  between  
type  II  diabetics  and  healthy  individuals.  To  correlate  the  plasma  
fibrinogen  level  with  HbA1c  value  in  type  II  diabetic  patients.   
Materials  and  methods:  This  is  cross  sectional  type  of  study. 75 type II  
diabetic  patients  of  age  between  40-60 years  taken  as  study group. 75 age 
and  sex  matched  healthy individuals taken as control group. Study  subjects  
were  selected  from  the  outpatient  department  of  Diabetology, CMCH.  
Patients  with  history  of  systemic  hypertension,  smoking,  vascular  
complications  of  diabetes,  infectious  and  inflammatory  conditions  were  
excluded  from  the  study. Blood  sample  was  taken  and analysed  for  plasma 
fibrinogen   and  HbA1c  by  turbidimetric  immunoassay  method.   
Results:  Statistical   analysis   was  done by using  student ‘t’test  and  pearson 
correlation coefficient.  In the present study,  mean  plasma fibrinogen  level  
was significantly  increased ( p  <0.0001) in  diabetic patients (276.6 ± 87) 
when  compared  to control group (160.3 ± 49) .  significantly  increased            
( p  <0.0001)   plasma  fibrinogen  level  was  observed  in  diabetics  with  
HbA1c  of  >7% (334.2±77)   and  also  positively  correlated  with  HbA1c  
value (r=0.8166). 
Conclusion: In  the  present  study ,   increased  plasma  fibrinogen  level 
(upper  limit  of  normal  range)  was  observed  in  diabetic  patients  having   
HbA1c  of  more  than 7%. It  could  be  due  to  advanced  glycation  end  
products  mediated  endothelial  injury,  apoprotein - a  and  increased  amount  
of  glycosylated  fibrinogen.  Elevated  plasma  fibrinogen  along  with  other  
blood   clotting  factors  produce  hypercoagulable  state  in  diabetes  mellitus.    
Increased  plasma  fibrinogen   also  involved  in  all  stages of  atherogenesis,  
which  results  in  formation  of  occlusive  thrombus.  So  the  measurement  of    
plasma  fibrinogen  is  considered  as  an  important  tool  to  assess  
cardiovascular  risk  in  diabetic  patients. 
Key  words: diabetes, fibrinogen,  HbA1c, cardiovascular risk  factor. 
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INTRODUCTION 
Diabetes  mellitus  is  a  chronic  disorder  of  metabolic  
derangements  sharing  the  common  feature  of  hyperglycemia  
resulting  from  impaired  action  and/or  reduced  secretion  of    
insulin 1. It  is  rapidly  achieving  the  potential  epidemic  status  in  
India  with  more  than  62  million  people  are  diagnosed  as  having  
diabetes.  In  2000,  India  has  attained  the  top  place  with  31.7  
million  diabetic  population  followed  by  china  with  20.8  million  
people  and  united  states  with  17.7  million  people 2. 
In  2010,  the  globally  estimated  population  of  diabetes  
mellitus   was  about  285  million,  among  them,  90%  type  II  
diabetics.  In  2013,  381  million  people  were  affected  globally   
with  prevalence  expected  to  almost  double  by  the  year  20303,4 .  
Increasing  prevalence  of  diabetes  in  developing  countries  like  
India  is  because  of  life  style  modifications  like  westernisation  of  
diet,  and  reduced  physical  activity.  Morbidity  and  mortality  due  
to  potential  macrovascular  and  microvascular  complications  of  
diabetes  are  very  high  and  it  is  responsible  for   major  health  care  
burden  to  the  community2.  
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 In  diabetes,  peripheral  neuropathy  is  accounting  for  about  
24.6%  of  complications,  which  is  followed  by  cardiovascular  
diseases (23.6%), nephropathy(21.1%),  retinopathy (16.6%),  and  foot  
ulcers (5.5%) 5.  Risk  of  developing  coronary  artery  disease  is  2-4  
fold  higher in patients  with  diabetes  than  in  non  diabetic  subjects2. 
According  to  WHO  2013,  cardiovascular  diseases  are  
considered  as  most  leading  cause  of  death,  worldwide.  Among  
the  cardivascular  diseases,  coronary  artery  disease  is  the  leading  
one  and  accounting  for  1.4  million  deaths  in  the  developed  
countries  and  5.7  million  deaths  in  the  developing  countries6.  
 In  80%  of  diabetic  patients  death  occur  due  to  thrombotic  
events,  among  which  75%  is  being  due  to  coronary  artery  
diseases  and  remaining  due  to  cerebrovascular  accidents  and  
peripheral  vascular  diseases.  Occurrence  of  premature  
atherosclerosis  and  extensive  vascular  diseases is  responsible  for  
plaque  rupture  and  subsequent  thrombus  formation  leading  onto  
cardiovascular  events 7,8. 
The  Framingham  heart  study  reported  that,  the  prevalence  
of  cardiovascular  disease  among  diabetic  patients  have  increased  
when  compared  to  non  diabetic  subjects9.  According  to  Silver  et  
al10,  in  patients  with  unstable  angina,  more  number  of  diabetic  
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patients (94%)  had  ulcerated  plaque  in  the  affected  coronary  
artery  than  non  diabetic  subjects  (60%).  Study  done  by  Moreno  
et  al11,  observed  that  atheroma  of  diabetic  patients  constitute  
large  amount  of  lipid  content,  increased  infiltration  with  
macrophages,  and  thrombosis  while  compared  to  non  diabetic  
subjects. 
In  diabetic  subjects  without  previous  history  of  myocardial  
infarction (MI), the  risk  of  associated  mortality  due  to  MI  is  equal  
to  that  of  non  diabetic  patients  with  previous  history  of  MI.  In  
2002,  Diabetes  was  named  as  coronary  artery  disease  equivalent  
by  NCEP  report 12.   
The  classical  risk  factors  responsible  for  cardiovascular  
diseases  in  diabetes  are  obesity,  smoking,  hypercholesterolemia,  
and  hypertension,  with  the  primary  trigger  being  the  
hyperglycemia 1.  But  the  excess  cardiovascular  risk  in  diabetes  
was  not  fully  explained  by  these  classical  factors.  An  analytical  
study  reported  that  >50%  of  subjects  with  coronary  artery  disease  
had  atleast  one  of  the  classic  risk  factors  and  about  20%  of  
subjects  had  coronary  artery  disease  without  the  presence  of  any  
classical  risk  factors.  In  addition  to  these  classical  risk  factors,  
some  other  novel  risk  factors  which  include  fibrinogen,  C-reactive  
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protein,  serum  uric  acid,  homocysteine,  LP(a)  and  tumor  necrosis  
factor  also  were  reported.  These  factors   accelerate  the  thrombotic 
process  and  resulting  in  the  cardiovascular  complications13.   
Fibrinogen  is  a  soluble  glycoprotein  present  in  the  plasma  
and  designated  as  first  clotting  factor  in  the  blood  coagulation  
cascade.  In case of  severe  injury  to  the  blood  vessel,  fibrinogen  is  
converted  into  insoluble  fibrin  and  forms  a  definite  clot  at  the  
site  of  injury.  Increased  fibrinogen  level  in  the  plasma  leads  to  
increased  the  blood  viscosity,  endothelial  injury  and  platelet  
aggregation,  which  plays  a  role  in  formation  of  atherosclerosis  
and  subsequent  thrombosis.   
In  1980,  Meade  and  colleagues,  first  found  out  the  
association  between  coronary  artery  diseases  and  high  levels  of  
plasma  fibrinogen.  Then  numerous  studies  had  proved  the  
association  between  hemostatic  parameters  and  atherosclerosis  
associated  cardiovascular  complications13.  Luciana  et  al  observed  
that  plasma  fibrinogen  level  was  significantly  elevated  in  patients  
with  CAD  when  compared  with  normal  healthy  subjects.  In  their  
study,  plasma  fibrinogen  level  was  correlated  with  the  severity  of  
CAD 15.  In  patients  with  known  coronary  artery  disease,  strong  
correlation  between  plasma  fibrinogen  level  and  recurrence  of  MI   
5 
 
was  observed.  Significant  association  between  plasma  fibrinogen  
level  and  cerebrovascular  diseases,  occlusive  peripheral  arterial  
diseases  was  also  observed  in  fewer  studies 16.   
 Levels  of  plasma  fibrinogen  may  vary   with  classical  
cardiovascular  risk  factors  like  diabetes  mellitus,  hypertension,  
smoking,  obesity  and   dyslipidemia 17.  Several  studies  have  
demonstrated  the  association  between  diabetes  mellitus  and  
increased  plasma  fibrinogen  level.  
 In  the  vascular  system,  primary  protection  against  the  
thrombosis  is  intact  endothelial  layer  of  the  vessel  wall.  This  
endothelium  gets  injured  in case  of  diabetes  by  different  
mechanisms  including,  endothelial  activation  by  advanced  
glycation  end  products  (AGE)  and  Protein  kinase-c  (PKC)  
activation  leading   to  altered  basement  membrane  structure  and  
vascular  permeability.  This  endothelial  injury  predisposes  
prothrombotic  state  and  accelerates  the  process  of  atherosclerosis  
in  diabetic  patients.   
Prothrombotic  state  is  associated  with  increased  plasma  
levels  of  many  coagulation  factors  including  fibrinogen,  factor  
VII,  XI,  XII,  Kallikrein, factor  VIII /vWF  complex,  impaired  
fibrinolysis  by  elevated  PAI-1  and  highly  resistant  nature  of  the  
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clot  to  the  fibrinolysis8.  Insulin  deficiency  associated  metabolic  
stress  in  the  liver  can  also  causes  increase in  plasma  fibrinogen  
especially  in  diabetes 18.   
The  elevated  plasma  fibrinogen  is  involved  in  early  steps  
of  plaque  formation  resulting  in  cardiovascular  morbidity  later.  
Fibrin  molecules  bind  with  oxidised  LDL  molecules  and  forming  
the  atheromatous  plaque.  Then  by  forming  occlusive  thrombus  at  
the  site  of  plaque  rupture,  increased  fibrinogen  level  is  involved  
in  the  late  cardiovascular  diseases  like  MI,  angina  and  stroke19.   
Various  studies   have  shown  that  diabetic  patients  with  
poor  glycemic  control  prone  for  high  risk  of  cardiovascular  
morbidity  and  mortality.  HbA1c  levels  has  been  utilised  to  assess  
the  glycemic  control  in  diabetic  patients. Only  fewer  studies  were  
carried  out  to  know  the  correlation  between  plasma  fibrinogen  
and  glycemic  control  in  diabetic  patients.  So  this  study  has  been  
done  to  evaluate  the  correlation  between  plasma  fibrinogen  level  
and  glycosylated  haemoglobin   (HbA1c)  in  type  II  diabetes  
mellitus  patients.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS  &  OBJECTIVES
7 
 
AIM AND   OBJECTIVES 
 
 To  study  the  level  of  plasma  fibrinogen  in  type  II  diabetes  
mellitus  patients  and  healthy  individuals. 
 To  compare  the  plasma  fibrinogen  level  between  type  II  
diabetes  mellitus  patients  and  healthy  individuals. 
 To  evaluate  the  correlation  between  plasma  fibrinogen  level  
and  glycosylated  haemoglobin  in  type  II  diabetes  mellitus  
patients. 
 To  evaluate  the  association  between  plasma  fibrinogen  level  
and  duration  of  diabetes  in  type  II  diabetes  mellitus  
patients. 
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REVIEW  OF  LITERATURE 
FIBRINOGEN 
Fibrinogen  is  a  multipotential  plasma  protein  synthesized  by  
the  liver  and  is  an  essential  component  of  blood  coagulation  
system.  It  is  also  responsible  for  viscous  nature  of  blood,  hence  
determines  the  blood  flow.  Increased  plasma  level  of  fibrinogen  
alters  vascular  homeostasis  by  causing  hypercoagulability.  This    
in  turn  increases  the  risk  of  cardiovascular  diseases  like  
myocardial  infarction,  stroke  and  peripheral  vascular  diseases 20. 
 
HISTORICAL  REVIEW 21 
In  1686,  Malphigi  separated  the  fibrin  fibers  from  clotted  
blood  which  is  devoid  of  red  blood  cells  and  serum,  then  
demonstrated  those  fibres  by  using  a  single  lens  microscope.   
In  1771,  a  junior  surgeon  named  William  Hewson  
identified  that  clot  formed  from  fluid  portion  of  blood  and  he  
also  observed  the  fast  erythrocyte  sedimentation  in  his  patients   
with  severe  inflammatory  pathology.   
In  1801,  Furcroy,  named  it  as  fibrin. He  also  demonstrated  
the  soluble  precursor  of  fibrin  present  in  the  plasma  and  it  was  
termed   “Fibrinogen”  by  Babington  in  1830.   
 ANDREW  BUCHANAN 
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In  1836,  Andrew  Buchanan,  a  young  surgeon  working  at  
Glasgow  university  described  in  detail  about  the  fibrin  by  his  
experiments  on  fresh  blood  clot.  He  took   the  fresh  blood  clot  in  
a  linen  cloth  and  by  squeezing,  separated  fluid  from  it.  When  
the  squeezed  out  liquid  was  added  to  hydrocele  fluid,  it  clotted. 
In  another  experiment,  he  diluted  the  blood  with  water  and  
allowed  it  to  clot  overnight.  Then  he  squeezed  the  liquid  from  
clotted  blood  and  mixed  it  with  hydrocele  fluid.  Fibrin present  in  
the  extracted  fluid  coagulated  the  hydrocele  fluid. By  these  
experiments  he  concluded  that,  fibrin  of  animal  fluids  exists  in  
the  form  of  solution. 
In  1859,  Denis,  first  separated  the  fibrinogen  by  salt  
precipitation  technique.  In  1879,  Hammerston,  obtained  the  pure  
form  of  fibrinogen  by  repeated  salt  precipitation  technique.   
In  1909,  Mellanby  who  worked  under  the  guidance  of  
Alexander  Schmidt,  prepared  fibrinogen  by  diluting   plasma  
followed  by  its  acidification  with  acetic  acid.  Hammersten  found  
out  that,  fibrin  is  formed  by  reaction  between  fibrinogen  and  
thrombin  in  1879. 
  
 
STRUCTURE  OF  FIBRINOGEN  AND  FIBRIN 
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Physiological  Aspects  of  Fibrinogen22,23 
Fibrinogen  is  one  of  the  major  plasma  protein  present  in  
the  blood.  It  is  a  high  molecular  weight  (340 kD)  soluble  
glycoprotein  that  circulates  in  the  plasma,  as  a  precursor  of  
insoluble  fibrin  molecule.  It  is  synthesised  mainly  in  the  liver, 
and  taken  up  by  the  platelets  in  smaller  amount  and  stored  in  
the   granules,  which  is  released  during  the  process  of  platelet  
activation  and  aggregation.  In  response  to  inflammatory  stimulus,  
it  is  also  secreted  by  the  lungs  and  intestinal  epithelium.  
 Fibrinogen  is  made  up  of  two  symmetric  subunits  of  3  
different  polypeptide  chains  namely  Aα,  Bβ,  γ. These  polypeptide  
chains  bind  with  one  another  by  covalent  disulfide  linkages.  
Amino  terminal  ends  of  all  3 pairs  of  chains  forming  the  central  
‘E’ domain,  whereas  carboxy  terminals  of  Bβ  and  γ  chains   
forming  two  peripheral  ‘D’ domains.  Amino  terminal  ends  
of  α  and  β  chains  designated  as  fibrinopeptide  A  and  B  
respectively.  FPA  and  FPB  act  as  repulsion  force  and  prevent  
polymerisation  of  fibrinogen.  Thrombin  cleaves  the  two  pairs  of  
these  peptides  during  the  conversion  of  fibrinogen  into  fibrin. 
Normal  level  of  plasma  fibrinogen  is  about  200-450 mg/dl24.  
Its  level  may  vary  from  100-700mg/dl 25. The  amount  of  
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fibrinogen  synthesised  is  between  1.7  to  5  g  per  day  with  mean  
plasma  level  of  about  250mg/dl.  Half  life  is  between  3-5  days.  
The  minimum  concentration  of  fibrinogen  required  for  hemostasis  
is  about  50-100mg/dl26 .   
FUNCTIONS  OF  PLASMA  FIBRINOGEN 25,27,28 
I. PRIMARY  HEMOSTATIC  PLUG  FORMATION: 
In  daily  life,  numerous  small  endothelial  damages  occur  in  
the  very  small  blood  vessels.  These  minute  injuries  are  corrected  
by  the  platelet  plug  formation.   Fibrinogen  promotes  platelet  
aggregation  by  binding  with  GP  IIb-IIIa  receptors  present  on  the  
adjacent  platelets  leading  to  temporary  hemostatic  plug  formation. 
II.  FORMATION  OF  DEFINITE  FIBRIN CLOT: 
In  case  of  severe  injury  to  the  vessel  wall,  blood  
coagulation  mechanism  starts  to  develop  within  15-20  seconds  
of  injury  and  prevent  further  blood  loss  by  forming  fibrin  
clot. 
BLOOD  COAGULATION  OCCURS  IN  3  MAJOR  STEPS:  
 Formation  of  prothrombin  activator  complex  by   extrinsic  
and  intrinsic  pathway. 
 Conversion  of  prothrombin  into  thrombin 
 Conversion  of  fibrinogen  into  fibrin 
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FORMATION  OF  PROTHROMBIN  ACTIVATOR  
COMPLEX 
Intrinsic  Pathway : 
This  mechanism  starts  with  exposure  of  blood  to  
subendothelial  collagen  tissue  through  damaged  vessel  wall  or  by  
injury  to  blood.  Initial  step  is  the  activation  of  factor   
 
XII  by  its  contact  with  collagen  tissue.  In  the  presence  of  
HMWK  and  prekallikrein,  activated  factor  XII  converts  the  factor  
XI  into  activated  factor  XI.  Factor  XIa  acts  as  enzyme  and  is  
involved  in  the  activation  of  factor  IX.  In  the  presence  of  
platelet  phospholipid  and  platelet  factor  3,  factor  IXa  converts  the  
factor  X  into  activated  factor  X. 
 
Extrinsic  Pathway: 
It  starts  with  the  injury  to  the  vessel  wall  or  surrounding  
tissues.  Injured  tissues  releases  thromboplastin.  Along  with  factor  
VII  and  Ca2+   the  tissue  factor  converts  factor  X  into  Xa. 
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Finally  the  “Prothrombin  activator  complex”  is  formed  
which  contains  factor  Va,  factor  Xa,  Ca2+  and  platelet  
phospholipid. 
 
Conversion  of  Prothrombin  into  Thrombin 
Factor  Xa  having  enzymatic  activity  converts  the  
prothrombin  into  thrombin , and  factor  Va  accelerating  this 
process. 
Conversion  of  Fibrinogen  into  Fibrin: 
It  is  the  final  step  of  blood  coagulation  mediated  by  
thrombin  which  acts  enzymatically  and  converts  fibrinogen  into  
fibrin.  It  occurs  in  3  steps.   
Proteolysis  of  Fibrinogen: 
Soluble  fibrinogen  contains  one  central  ‘E’  domain  and  two  
peripheral  ‘D’  domains.  Thrombin  binds  with  fibrinogen  on  its  
central  domain,  then  proteolytically  cleaves  the  bond  between  
fibrinopeptides  and  aminoterminal  ends  of  polypeptide  chains.  
fibrinopeptide  A  and  B  are  released  from  Aα  and  Bβ  chain  
respectively  forms  fibrin  monomer.   
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Various  forms  of  fibrin  monomers  are  ‘desA  fibrin’  formed  
after  rapid  removal  of  fibrinopeptide  A,  ‘desAB  fibrin’  produced  
after  the  release  of  both  fibrinopeptide  A  and  B  and  ‘desB  
fibrin’  formed  rarely  after  removal  of  Fibrinopeptide  B. 
Polymerisation  of  fibrin  monomer: 
Fibrin  monomers  join  laterally  to  form  fibrin  oligomer.  
whereas  more  fibrin  monomers  unite  to  form  polymer  called  
“Protofibril”.  Many  protofibrils  join  laterally  and  forms  thick  
fibrin  fibers.  This  fibrin  polymerisation  process is  mediated  by  
thrombin  and  factor  XIIIa. 
Stabilisation  of  fibrin  polymer: 
Factor  XIIIa  and  Ca2+  mediates  the  covalent  cross  linking  
of  fibrin  polymers  within  the  fibrin  bundle.  This  covalent  cross  
linkages  between  fibrin  polymers  strengthen  the   fibrin meshwork  
and  stabilised  blood  clot  is  formed  with  entrapment  of  Red  blood  
cells  and  Platelets  inside  the  blood  clot 
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STEPS  INVOLVED  IN  CONVERSION  OF  FIBRINOGEN  
INTO FIBRIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. BLOOD  VISCOSITY 29 
It  is  a  measure  of  intrinsic  resistance  to  the  blood  flow.  
Blood  viscosity  is  1.6  times  more  than  the  water  by  the  presence  
of  plasma  proteins  like  globulin  and  fibrinogen.  Asymmetric  
elongated  structure  of  Fibrinogen is  responsible  for  the  viscous  
nature  of  blood. 
 
Soluble  Fibrinogen 
PROTEOLYSIS      
     Thrombin 
      Ca2+ 
Fibrin  Monomer 
(desA,  de AB,  desB) 
POLYMERISATION    Factor XIIIa,     
    Thrombin 
Thick fibrin meshwork 
STABILISATION  Factor XIIIa 
Stabilised  Blood  Clot 
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IV. ERYTHROCYTE  SEDIMENTATION 30 
When  the  blood  column  is  allowed  to  standstill  in  a  tube,  
the  rate  at  which  red  blood  cells  that  settles  down  is  determined  
by  the  amount  of  fibrinogen  in  the  blood.   
Red  blood  cells  having  negatively  charged  sialic  acid  
molecules  on  their  cell  membrane  which  act  as  repulsion  force  
separates  the  red  blood  cells  from  one  another.  This  repulsion  
force  is  also  called  as  zeta  potential.  Fibrinogen  neutralises  these  
zeta  potential  and  makes  the  red  blood  cells  to  stick  with  each  
other  by  which  it  increases  the  rate  of  settling  down  of  red  
blood  cells . 
 
CONDITIONS  INCREASING  FIBRINOGEN  LEVEL 
There  are  so  many  factors  influencing  plasma  fibrinogen  
level.  The  factors  contributing  to  increase  in  plasma  fibrinogen  
level  are  conventional  cardiovascular  risk  factors  like  diabetes  
mellitus,  systemic  hypertension,  hypercholesterolemia,  smoking  and  
obesity.   
Others  are  advancing  age,  menopause,  malignancies,  
infections,  inflammations  and  oral  contraceptive  pills  intake.41 
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PATHOPHYSIOLOGIC  ASPECTS  OF  FIBRINOGEN  IN  
RELATION  TO  CARDIOVASCULAR  DISEASES 
Fibrinogen  and  its  active  product  called  fibrin  play  an  
important  role  in  atherosclerosis  and  thrombosis  by  altering  blood  
rheology,  causing  endothelial  injury  and  promoting  platelet  
aggregation 29. 
 
ATHEROSCLEROSIS: 
The  intimal  lesion  known  as  “Atheroma”  protrudes  into  the  
vessel  lumen  is  the  characteristic  feature  of  atherosclerosis.  This  
atheromatous  plaque  is  made  up  of  three  portions.   
1. Superficial  fibrous  cap  contains  collagen  and  smooth  
muscle  cells.   
2. Sides  of  fibrous  cap,  which  is  made up  of  smooth   
muscle  cells  and  macrophages.   
3. Necrotic  core  which  is  deep  to  fibrous  cap  contains     
lipoprotein (a)  and  low  density  lipoprotein,  lipid  laden    
macrophages called  foam  cells,  dead  cell  debris,  
fibrin,  microthrombus  and  other  plasma  proteins 31. 
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ROLE  OF  FIBRINOGEN  IN  ATHEROSCLEROSIS: 
Increase  in  plasma  fibrinogen  level  in  turn  increases  blood  
viscosity.  This  change  in  viscosity  increases  the  responsiveness  of  
platelets  to  the  subthreshold  level  of  ADP,  which  is  the  
important  substance  promoting  platelet  aggregation.  
Normally  tunica  intima  of  arterial  wall  contains  plasma  
proteins  like  lipoprotein (a),  fibrinogen  and  low  density  
lipoprotein.  These  proteins  are  also  present  in  the  atherosclerotic  
vessel  wall  and  their  concentration  depends  on  plasma  
concentration 32.   
In  case  of  endothelial  injuries,  repairing  processes  are  
activated  to  maintain  the  vessel  homeostasis.  These  processes  
include,  platelet  aggregation,  movement  of  leukocytes  across  
endothelial  cell  layer  and  proliferation  of  smooth  muscles  in  the  
vessel  wall.  All  these  events  occur  in  a  co-ordinated  manner  by  
various  cytokines,  growth  factors  and  adhesion  proteins.  Changes  
in  any  of  these  events  by  triggering  factors  like  increased  plasma  
fibrinogen  during  repair  process  lead  onto  lipid  deposition,  extra  
cellular  matrix  protein  accumulation,  cell  death  resulting  in  
advanced  atheromatous  plaque  formation 33. 
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Fibrinogen  is  a  multipotential  protein  involved  in  all  stages  
of  atheromatous  plaque  development.  On  increased  plasma  
fibrinogen  level,  more  amount  of  fibrin  is  deposited  in  the  tunica  
intima  leading  to  endothelial  injury  and  edema.  The  initial  feature  
of  early  proliferative  lesion  is “ Intimal  edema”.   Fibrin  acts  as  
stimulant  for  smooth  muscle  migration  into  intima  and  its  further  
proliferation.   
Fibrin  also  continuously  split  to  form  fibrin  degradation  
products.  These  FDPs  have  mitogenic  activity  and    maintaining  
the  fibrin  induced  smooth  muscle  cell  proliferation.  FDPs  also  
stimulate  collagen  synthesis and  alters  endothelial  permeability.  
Fibrin  also  bind  lipoprotein (a)  and  low  density  lipoprotein  with  
more  affinity  and  promotes  their  accumulation  and  prevent  their  
migration  within  the  lesion 34,35.    
Increased  fibrinogen  gets  deposited  in  the  vessel  wall;  
fibrin  molecules  may  form  the  mural  thrombus  on  the  intact  
surface  of  plaque,  or  deposit  within  the  fibrous  cap  or  in  the  
lipid  rich  portion  of  atheromatous  plaque  or  spread  diffusely  
throughout  the  plaque.  This  may  also  be  associated  with  
decreased  intimal  fibrinolysis  and  reduced  plasmin  concentration  
in  the  blood  as  seen  in  cardiovascular  diseases 20.   
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By  binding  with  adjacent  platelets ,  it   promotes  platelet  
aggregation,  and  by  forming  definite  clot  over  the  ruptured  
plaque  involved  in  the  dreadful  events  of  atherothrombosis 19. 
 
 
STUDIES  RELATED  TO  FIBRINOGEN  AND  
CARDIOVASCULAR  DISEASES 
Cardiovascular  diseases  including,  coronary  vascular  diseases  
and  cerebrovascular  diseases,  are  nowadays  the  major  cause  of  
morbidity  and  mortality  worldwide  and  responsible  for  21.9%  of  
total  deaths.  By  the  year  2030,  this  percentage  value  may  
increase  to  26.3% 36 . 
Conventional  cardiovascular  risk  factors  does  not  predict  all  
cardiovascular  events.  In  an  analytical  study  of  more  than  
1,20,000  persons  with  coronary  artery  disease,  about  20%  subjects  
have  manifested  coronary  artery  disease  without  the  presence  of  
conventional  risk  factors  like  systemic  hypertension,  diabetes,  
smoking  and  dyslipidemia.  More  than  50%  subjects  had  only  one  
of  the  above  conventional  risk  factors.  
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These  observations  suggested  the possibility  of  other  risk 
factors  in  the  occurrence  of  coronary  artery  disease  and  focussed  
the experimental research into the identification  of  novel  risk  factors 
like  increased levels of plasma fibrinogen, WBC count, homocysteine,  
C  reactive  protein,  uric  acid  and  adiponectin  levels13. 
Several  risk  factors  like  systemic  hypertension,  diabetes  
mellitus,  dyslipidemia  and  smoking  are  associated  with  the  
pathogenesis  of  coronary  atherosclerosis.  Along  with  these  
conventional  risk  factors,  more  number  of  newer  risk  factors  like  
increased  lipoprotein-a,  homocysteinemia,  increased  PAI-1,  more  
number  of  reactive  oxygen  species,  angiotensin  converting  enzyme  
polymorphism  are  also  added  in  the  pathogenesis  of  
atherosclerosis.   
Inflammatory  products  like  C-reactive  protein  and  fibrinogen  
are  also  responsible  for  atherosclerosis.  These  are  highly  sensitive  
and  produced  in  response  to  inflammatory  cytokine  IL-6,  which  
is  the  major  factor  inducing  the  synthesis  of  acute  phase  proteins 
According to  Yuksel  Cavusoglu  et  al 37,  mean  CRP  and  fibrinogen  
values  were  significantly  high,  whereas  AT-III  level  was  
significantly  low  in  patients  with  Coronary  artery  diseases  while  
comparing  with  that  of  patients  without  Coronary  artery  diseases. 
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In  1987,  The  Framingham  heart  study  observed   statistically  
significant  association  present  between  plasma  fibrinogen  level  
and  coronary  artery  disease.  They  selected  1315  subjects  without  
coronary  artery  diseases.  Over  the  study  period  of  12  years  165  
men  and  147  women  subjects  developed  cardiovascular  diseases.  
In  both  sexes,  Cardiovascular  disease  risk  is  positively  correlated  
with  the  high  plasma  fibrinogen  level  of  more  than  126  to  696  
mg/dl.  Plasma  fibrinogen  level  was  also  significantly  associated  
with  other  cardiovascular  risk  factors  like  systemic  hypertension,  
obesity,  smoking  and  diabetes  mellitus.  By  this  study,  increased  
plasma  fibrinogen  level  was  considered  as  a  predictor  of  
cardiovascular  diseases  and  suggested  to  be  included  in  the  
cardiovascular  risk  profile38. 
Northwick  park  heart  study:  Meade  et  al,  analysed  the  
involvement  of  thrombotic  factors  in  the  development  of  coronary  
artery  diseases.  They  have  investigated  1511  male  subjects  of  age  
between  40-64  years.  Association  between  Coronary  artery  disease  
and  factor  VII  activity,  fibrinogen  and  cholesterol  levels  were  
62%,  84%,  43%  respectively.  This  indicated  that  the  strong  
association  was  present  between  fibrinogen  and  Coronary  artery  
diseases,  especially  in  young  adults  than  in  old  age  in  this  study.  
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They  have  also  observed  strong  association  between  Coronary  
artery  disease  and  smoking  may  be  mediated  through  increased  
plasma  fibrinogen39. 
In  another  prospective  epidemiological  study,  2167  males  
and  941  females  in  the  average  age  of  48  years  were  recruited  
and  studied  over  the  period  of  29  years. During  the  follow  up  
period,  231  males  and  36  females  died  because  of  Coronary  
artery  disease.  Factor  VII  activity  measured  at  the  time  of    
recruitment  was  strongly  associated  with  mortality  due  to  
coronary  artery  disease  in  both  sexes.  Whereas  the  measured  
fibrinogen  level  was  strongly  correlated  with  mortality   due  to  
coronary  artery  disease  in  men  but  not  in  women.  This  
correlation  persists  even  after  adjusting  for  confounding  factors.  
This  strong  association  also  confirmed  at  the  time  of  6  year  
follow up  measurement  of  fibrinogen  level  and  factor  VII activity .  
They  have  suggested  that,  the  hemostatic  factors  were  also  
involved  in  morbidity  and  mortality   of  coronary  artery  disease 40. 
The  major  three  mechanisms  involved  in  the  basis  of  
pathogenesis  of  atherosclerosis  are  endothelial  dysfunction,  
thrombosis  and  inflammation.  Fibrinogen  and  its  metabolites  
produce  endothelial  dysfunction.  Fibrin  accumulated  in  the  intimal  
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layer  of  vessel  wall  binds  with  the  fibronectin,  which  triggers  the  
cell  migration  and  adhesion.  They  also  stimulate  the  mitogenesis,  
collagen  synthesis,  leukocyte  migration  and  increase  in  capillary  
permeability. 
Pro  inflammatory  cytokines  like  IL-6  and  TNF-α  released  
from  the  blood  vessels,  adipose  tissue  and  cardiac  myocytes  
inducing  the  synthesis  of  fibrinogen,  which  acts  via  prothrombotic  
mechanism  involved  in  the  formation  of  atheromatous  plaque,  the  
initial stage of coronary artery diseases.  This  indicates  that  the  
fibrinogen is important etiological factor responsible for coronary 
artery diseases rather than the byproduct  of  atheromatous  plaque 41,42. 
According  to  Shojaie  et  al,  high  levels  of  fibrinogen  is  
considered  as  risk  factor  for  premature  coronary  artery  disease  in  
persons  of  <55  years  of  age43. 
Green  D  et  al observed  that,  high  levels  of  fibrinogen  
involved  in  the  subclinical  atherosclerosis.  They  also  found  that,  
there  was  strong  positive  correlation  present  between  high  levels  
of  fibrinogen  in  young  adults  and  prevalence  of  coronary  artery  
calcification  and  increased  carotid  artery  intimal- medial  thickness  
in  middle  age44. 
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Framingham  offspring  study:  James  J. Stec  et  al  concluded  
that,  plasma  fibrinogen  level  was  increased  in  patients  with  
cardiovascular  diseases  than  those  without  CVD  and  increase  in  
fibrinogen  level  also correlated  with  other  conventional  
cardiovascular  risk  factors17. 
According  to  Amanda  J  lee,  patients  with  history  of  
systemic  hypertension,  stroke,  diabetes  mellitus  and  in  persons  
with  intermittent  claudication,  the  mean  plasma  fibrinogen  level  
was  high  while  comparing  with  that  of  healthy  subjects.  In  
persons  with  myocardial  infarction,  angina,  and  in  persons  with  
family  history  of  premature  heart  disease  before  the  age  of  60  
years  plasma  fibrinogen  level  was  significantly  higher  than  the  
normal  healthy  subjects45. 
Gheye.S  et  al,  observed  that  in  Indian  people  significant  
association  present  between  elevated  plasma  fibrinogen,  abdominal  
obesity  and  coronary  artery  disease46.  
 Luciana  et  al,  also  observed  that  plasma  fibrinogen  level  
was  significantly  elevated  in  patients  with  coronary  artery  disease  
while  comparing  with  that  of  normal  healthy  subjects.  The  
plasma  fibrinogen  level  correlated  with  the  severity  of  coronary  
artery  disease  15. 
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Increasing  incidence  of  Coronary  artery  disease  in  the  
young  adults  (CADY)  suggests  the  involvement  of  non-
conventional  newer  risk  factors  like  thrombogenic  factors,  
infections,  inflammation  and  psychosocial  factors47. 
In  the  study  by  Murat  saruc  et  al,  the  levels  of  Protein-C,  
Protein-S  were  significantly  reduced  and  plasma  fibrinogen  level  
was  significantly  elevated  in  patients  with  coronary  artery  disease    
than  in  controls.  Significant  changes  in  above  parameters  also  
present  between  patients  with  single  vessel  disease  and  in  
patients  with  double  or  triple  vessel  disease48. 
J  stuart  and  co  workers  described  that,  Patients  with  severe  
lower  limb  atherosclerosis  showed  significant  increase  in  platelet  
count,  fibrinogen, neutrophilic  leukocytosis, and  defect  in  platelet  
function  and  fibrinolysis.  These  abnormalities  are  together  called  
haematological  stress  syndrome  seen  in  chronic  vascular  diseases  
and  responding  to  formation  of  atherothrombosis 49.      
Robert  M.  Corney  et  al,  found  that,  in  patients  with  
coronary  artery  disease  and  depression,  fibrinogen  levels  were  in  
the  high  normal  level.  These  elevated  fibrinogen  levels  were  in  
significant  negative  correlation  with  HRV  parameters.  Because  of  
depression  associated  decreased  parasympathetic  activity,  vagal  
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inhibition  over  the  proinflammatory  cytokines  release  became  
reduced,  lead  on  to  increased  plasma  fibrinogen  level.  This  
plasma  fibrinogen  inturn  increases  the  risk  of  mortality  in  
patients  with  coronary  artery  disease  and  depression 50. 
The  interpretation  of   Raja  Babu  Panwar  and  his  co  
workers  in  their   study  is  that,  thrombogenic  factors  like,  elevated  
plasma  fibrinogen  level,   homocysteinemia,  smoking,  inadequate  
ingestion  of  fruits  and  vegetables  and  atherogenic  factors  like  
high  fat  intake,  systemic  hypertension,  dyslipidemia  (  high LDL,  
low  HDL,  high  triglycerides)  were  involved  in  the  development  
of  premature  coronary  artery  disease 51. 
In  the  cohort  study  done  by  A.R.Rudnika  and  co-workers,  
strong  association  was  observed  between  plasma  fibrinogen  level  
and  cardiovascular  diseases  like  coronary  artery  disease  and stroke  
even  after  adjustments  made  for  all  other  risk  factors 52. 
De  Maat  MP  et  al  described  that,  plasma  fibrinogen  level  
was  significantly  higher  in  patients  with  symptoms  of  angina  
while  compared  to  healthy  control  group   and  there  is  difference  
in  plasma  levels  of  IL-6  between  patients  and  healthy  controls  
while  no  difference  was  observed  in  the  CRP  level53. 
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Atherosclerosis  Risk  In  Communities  (ARIC)  study:   
plasma  fibrinogen  was  increased  in  persons  with  prevalent  
cardiovascular  diseases  while  compared  to  healthy  subjects.  It   
also   positively  correlated  with  stroke,  intermittent  claudication  
and  carotid  atherosclerosis54. 
TYPE  II  DIABETES  MELLITUS 
Definition: 55 
Diabetes  mellitus  refers  to  prolonged  hyperglycemia  
resulting  from  group  of  metabolic  dearrangements  involving  major  
nutrients  like  carbohydrate,  lipids,  and  proteins  caused  by   
impaired  insulin  action  with  or  without  reduced   insulin   secretion.  
Historical  aspects :55 
In  ancient  era,  Sushruta,  father  of  surgery  gave  an  
understandable  view  of  diabetes  in  the  form  of  etiological  factors,  
clinical  features  and  complications.  He  also  introduced  the  rules  
of  medical  and  surgical treatments  for  the  diabetes.  At  that  time  
diabetes  was  named  as  “Madhumeha”   ( means  “rain  of  honey”),  
because  of  the  sweet  taste  urine  of  patients  with  diabetes. 
In  1st  century  AD,  The  Greek  physician  arateus  of  
Cappadocia,   coined  the  term  “diabetes”  means  “siphon”  that  is  
liquefaction  of  flesh  and  bones  into  urine.  
32 
 
In  1674,  Thomas  Willis,  professor  at  oxford  rediscovered  
the  sweety  taste  of  urine  of  patients  with  diabetes  by  tasting  that  
urine. 
Cullen  (1710-1790):  He  gave  the  full  name  diabetes  
mellitus by  adding  the  term  “mellitus”  (‘mel’  means  ‘honey’)  with  
diabetes. 
In  1788,  Thomas  Cowley  found  out  that  shrunken  pancreas  
studded  with  stones  in  an  autopsy  of  diabetic  patient. 
In  1798,  John  Rollo  found  out  the  relationship  between  
hyperglycemia  and  diabetes  mellitus. 
In  1869,  Paul  langerhans,  a  german  medical  student  
described  that  different  types  of  cells  combined  and  presented  as  
islets.  These  islets  were  spread  throughout  the  pancreas  with  
majority  in  the  tail  portion  of  pancreas.  Later  it  was  named  as  
“Islets  of  langerhans”.   
20  years  later,  role  of  pancreas  in  diabetes  was  
demonstrated  by  Oscar  Minkowski  and  Joseph  Von  Mering.  They  
were  surgically  removed  the  pancreas  in  two  dogs.  On  the  next  
day  both  dogs  developed  fatal  diabetes  with  polyuria.  Then  the  
dogs  life  were  saved  by  placing  fresh  piece  of  pancreatic  tissue  
underneath  the  skin. 
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DIAGNOSTIC  CRITERIA  FOR  DIABETES  MELLITUS:1 
 Symptoms  of  diabetes  mellitus  with  random  blood  sugar  
>200  mg/dl  (or) 
 Fasting  plasma  glucose  (FPG)  concentration >126  mg/dl  (or) 
 2  hours  plasma  glucose  concentration  >200mg/dl  during  
oral  glucose  tolerance  test. 
Most  reliable  method  for  diagnosis  is  measurement  of  FPG  
concentration. 
CRITERIA  FOR  DIAGNOSIS  OF  DIABETES  AND  
PRE  DIABETES 56 
 
Test 
 
Normo 
glycemia 
 
IFG 
 
IGT 
 
Highrisk 
 
Diabete
s 
FPG 
(mg/dl) 
<100 100-125 
 
  >126 
2 hours 
PG(mg/dl) 
<140  140-199  >200 
HbA1c (%)    5.7-6.4 >6.5 
 
  
 
CHARLES.H.BEST AND FREDERICK.G.BANTING 
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PHYSIOLOGICAL  BASIS  OF  INSULIN  SECRETION: 
Insulin  is  the  primary  anabolic  hormone  synthesized  in  the  
beta  cells  of  pancreatic  islets,  and  is  important  for  the  regulation  
of  glucose  and  free  fatty  acids  levels  in  the  blood.  It  is  a  
polypeptide hormone of the gene family of IGF-I, IGF-II and relaxin57. 
HISTORICAL  ASPECTS:55 
On  14th April  1921,  Frederick.G.Banting,  an  orthopaedic  
surgeon  along  with  his  medical  student  Charles.H.Best  started  his  
work  on  isolation  of  antidiabetic  hormone  from  the  pancreas.  He  
used  his  former  professor  JJR  Macleod’s  laboratory  for  research  
work.  In  1922,  Banting  and  Best  successfully  extracted  the  
hormone  and  injected  it  into  the  pancreas  removed  dogs.  Then  
the  dogs  immediately  recovered  from  their  symptoms. 
In  1923,  for  their  wonderful  job  on  discovery  of  insulin,  
Banting  and  Macleod  were  awarded  with  “NOBEL  PRIZE”.  
Banting  provided  a  part  of  prize  money  to  the  Best.  Likewise  
Macleod  shared  with  JB Collip. 
Professor Macleod and JB Collip along with his co-workers 
have successfully purified  the insulin and first time injected it into a 
14 years old boy Leonard Thompson. Daily injections reduced  his  
blood  sugar  level  and  urine  sugar.  Ketone  bodies  also  
disappeared  from  his  urine.  
ISLET  OF  LANGERHANS 
 
 
 
 
STRUCTURE  OF  INSULIN  AND  PROINSULIN 
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In  1934,  Svedberg  determined  the  molecular  weight  of  
insulin.  In  the  middle  of  1950s,  Frederick  sanger  described  about  
the  molecular  structure of   insulin  and  got  “NOBEL  PRIZE”  for  
his  work  on  1958. 
 STRUCTURE 58 
Insulin  is a  51  aminoacids  containing  polypeptide  hormone  
made  up  of  two  peptide  chains  namely  α  and  β,   α  chain  with  
21  aminoacids  and  β  chain  with  30  aminoacids.  These  two  
peptide  chains  joined  by  two  disulphide  bonds  and  one  more 
disulphide  bond  is  present  within  the  α  chain  itself.  Molecular  
weight  is  about  5808  Da. 
BIOSYNTHESIS  24,57,59 
Insulin  gene  located  on  the  short  arm  of  chromosome  11  
and  it  codes  the  precursor  hormone  called  Preproinsulin  which   is  
a  108  aminoacids  containing  polypeptide  hormone   synthesized  in  
the  polyribosomes. 
In  the  endoplasmic  reticulum,23  amino  acid  containing  N  
terminal  signal  peptide  is  removed  from  Preproinsulin  by  the  
action  of  microsomal  enzymes  and  Proinsulin  is  formed. This  
proinsulin  constitutes  A and  B  polypeptide  chains  of  insulin  and  
  
MECHANISM  OF  INSULIN  RELEASE 
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‘C’peptide.   ‘C’ peptide  otherwise  called  as  connecting  peptide  
which  facilitates  the  folding  of  proinsulin.   
In  the  Golgi  apparatus,  membrane  bound  secretory  granules  
are  formed  by  the  packaging  of  proinsulin.  The  secretory  
granules  also  contain  propertein  convertase  1/3  and  2  enzyme  
which  cleaves  the  ‘C’peptide  from  proinsulin  molecule  and  forms  
the  mature  active  hormone  called  “INSULIN”.  
Zinc  combined  with  insulin  forms  zinc-insulin  crystals  
which  occupies  the  dense  central  core  of  the  granules  where  as  
clear  zone  between  the  dense  core  and  granular  membrane  is  
occupied  by  the   ‘C’peptide.     
MECHANISM  OF  SECRETION 57,59 
The  major  stimulus  for  the  insulin  secretion  is  blood  
glucose.  Glucose  enters  into  the   β  cells  through  GLUT-2  
transporters  present  on  the  cell  membrane  by  facilitated  diffusion.  
Glucose  is  converted  into  glucose  6  phosphate  by  the  enzyme  
glucokinase,  and  is  considered  as  the  first  rate  limiting  step  in  
the  insulin  secretion  process.   
Glucokinase  acts  as  glucose  sensor  and  determines  the  rate  
of  insulin  secretion.  If  blood  glucose  is  more,  more  glucose  goes  
inside  the  beta  cells,  rate  of  glycolysis  and  ATP  production  
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increases  and  which  inturn  increases  rate  of  insulin  secretion.  If  
blood  glucose  is  less,  less  glucose  goes  inside  the  beta  cells,  rate  
of  glycolysis  and  ATP  production  decreases  and  which  in turn  
decreases  rate  of  insulin  secretion. 
Oxidation  of  glucose  in the  glycolytic  pathway  finally  
produces  ATP  molecules.  K ATP  channels  are  closed  by  the  
elevated  levels  of  ATP.  This  will  lead  to  decrease  in  K+ efflux  
and  produce  depolarisation  inside  the  cell.  SUR  and  KIR  6  &  2  
are  the  components  of  K ATP  channels,  and  these  combine  to  
form  the  large  octameric  channel  for  the  passage  of  K+  ions. 
Depolarisation  causes  opening  up  of  voltage  gated  Ca 2+  
channels  and  increases  intracellular  Ca 2+  level. Increased  Ca 2+  
causes   microtubule  mediated  exocytosis  of  granules  and  release  
their  contents  into  the  blood.  90-97%  of  released  contents  are  
insulin  with  equal  quatities  of  ‘C’peptide.  The remaining  released  
contents  are  proinsulin.  About  50%  0f  secreted  insulin  undergo 
first  pass  metabolism  in  the  liver  before  reaching  the  peripheral  
circulation.   
‘C’ peptide  does  not  have  specific  biological  action,  and  the  
measurement  of  ‘C’ peptide  level  by  radioimmunoassay  provides  
an  index  for  internally  secreted  insulin  level. 
 REGULATION OF INSULIN SECRETION 
 
STIMULATION  
 
 
INHIBITION 
NUTRIENTS: 
 Glucose(primary stimulus) 
 Aminoacids  
 Fatty acids  
 
 
HORMONES: 
 Glucagon 
 GI peptides-GIP,GLP-I, 
Gastrin, CCK  
 
 
 Somatostatin  
 
ANS : 
 Parasympathetic 
stimulation(M4R) 
 Sympathetic stimulation 
(β2R)  
 
 
 Sympathetic 
stimulation(αR)  
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RATE  OF  INSULIN  SECRETION 56,60 
Normal  insulin  release  occurs  in  a  pulsatile  manner.  It  is  
characterised  by  rapid  oscillations  for  each  8-15  minutes  with  
superimposition  of  slower  oscillations  in  every  80-150  minutes.  
Basal  secretion  rate  in  human  is  about  0.5-1  U/hr  or  40  U/day  
because  of  burst  off  secretion  after  each  meal. 
METABOLISM  OF  INSULIN59 
Insulin  circulates  in  free  form  and  its  half  life  is  about  
5minutes. It  is  metabolised  by  the  enzyme  insulinase  present  in  
the  kidney  and  liver. 
FACTORS  REGULATING  INSULIN  SECRETION 56,60 
Carbohydrate  nutrients: 
Glucose  is  the  essential  food  substance  involved  in  the  
regulation  of  insulin  secretion.  Insulin  secretion  in  response  to  
oral  glucose  is  more  than  the  intravenously  administered  glucose.  
This  is  because  of  incretin  hormones.   
Incretins  are  the  hormones  secreted  by  the  mucosa of  small  
intestine  in  response  to  orally  ingested  carbohydrates  and  they  are  
GLP-I  and  GIP .  Incretins   primes  the  beta  cells  to  increase  their  
response  to  orally  ingested  glucose. This  phenomenon  is  called as 
“INCRETIN  EFFECT”.  
  
 
 
INCRETIN  EFFECT 
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Intravenous  infusion  of  glucose  at  a  fixed  rate   causes  
biphasic  insulin  secretion .  
Phase I:  Rapid  phase, peak  attained  within  1-2  minutes  
followed  by  abrupt  fall  and  reaches  the  basal  level in  the  next  
5minutes. This  is  because  of  release  of  preformed  insulin  from  
the  secretory  granules. Lack  of  1st  phase  insulin  secretion  with  
postprandial   hyperglycemia   is  the  early  feature  of  type  II  
diabetes. 
Phase II:  Insulin  secretion  increases  again  but  in  a  slow  
manner  and  attains  the  second  peak.  This  phase  depends  on  rise  
in  blood  glucose  level.  Decreasing  2nd  phase  due  to  deterioration  
of  β  cell  function   results  in  marked  hyperglycemia  in  diabetics. 
This  biphasic  response  is  due  to  acute  stimulating  effect  of  
glucose  on  insulin  release. But  prolonged  exposure  to  higher  
glucose  level  decreases  the  insulin  synthesis  and  secretion  by  
decreasing  the  expression  of  insulin  gene   in  the  beta  cells  
(glucotoxicity). 
PHASES  OF  INSULIN  SECRETION 
 
 
 
MECHANISM  OF  ACTION  OF  INSULIN 
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Non carbohydrate  nutrients: 
Essential  aminoacids  like  arginine,  leucine  and  lysine  
increases  the  insulin  secretion . Lipids  and  their  metabolites  have  
minimal  effects  on  insulin  secretion. Ketone  bodies  increases  the  
insulin  secretion  during  starvation. 
Hormonal  factors: 
Hormones  increasing  the  insulin  secretion  include  GI  
hormones  like  GIP, -GLP-I, CCK  and  glucagon,  glucocorticoids,  
sex  steroids, prolactin , placental  lactogen. 
Neural  factors: 
Vagus  nerve  stimulates  the  insulin  secretion  via  M4  
receptor  and  sympathetic  fibres  inhibit  insulin  secretion  via  α1  
receptor, and  stimulates  the  insulin  secretion  via  β  receptor.  
Stimulation  of  ventromedian  nucleus  of  hypothalamus  decreases  
the  insulin  release. 
MECHANISM  OF  ACTION57 
Insulin  elicits  its  action  by   binding  with  insulin  receptor  
located  on  the  cell  membrane  of   target  tissues. 
Steps  involved  in  mechanism  of  action: 
Insulin  diffuses  across  the  capillary  wall  and  reaches  the  
target  tissues  where  it  binds  with  α  subunit  of  insulin  receptor.  
ACTIONS  OF  INSULIN 
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Autophosphorylation  of   β  subunit  occurs  by  the  activation  of  
tyrosine  kinase  enzyme.  Phosphotyrosine  residues of  β  chain  
causes  recruitment  of  adapter  proteins  like  IRS,  Shc  and  APS  
protein.  Finally  the  effects  are  expression  of  genes  within  the  
nucleus,  synthesis  of  proteins  like  glucokinase,  
phosphofructokinase,  deactivation  and  activation  of  enzymes  
involved  in  glucose  and  fatty  acid  metabolism  and  translocation  
of  GLUT  to  the  cell  membrane. 
 
PHYSIOLOGICAL  ACTIONS  OF  INSULIN 28,57,59 
ACTIONS  ON  METABOLISM: 
Insulin  is  the  major  endocrine  hormone  involved  in  the  
metabolism  of  carbohydrate,  lipids  and  proteins.  
ON  CARBOHYDRATE  METABOLISM: 
In  a  normal  healthy  person,  from  the  orally  ingested  
glucose  about  50%  is  used  for  giving  energy  to  the  body  tissues  
by  glycolysis.  About  40%  is  converted  and  stored  as  fat  and  
10%  of  glucose  is  stored  as  glycogen.  This  type  of  balance  
between  utilisation  and  storage  of  energy  is  mainly  because  of  
insulin  hormone  .   
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Insulin  exerts  its  action  mainly  by  acting  on  effector  organs  
like  skeletal  muscle,  adipose  tissue  and  liver.  Net  effect  of  
insulin  on  carbohydrate  metabolism  is  to  decrease  the  blood  
glucose  level,  and  is  considered  as  the  only  effective  
“ANTIDIABETOGENIC  HORMONE”  in  the  body. 
Insulin  decreases  the  blood  glucose  level  by  increasing  the  
glucose  uptake  in  the  target  tissues.  This  is  achieved  by  
translocation  of  GLUT  transporters  to  the  cell  membrane.  Insulin  
dependent  glucose  uptake  occur  in  the  muscle  tissues  like  skeletal  
muscle,  cardiac  muscle,  smooth  muscle  and  adipose  tissues,  
WBCs,  Mammary  glands.  Insulin  independent  glucose  uptake  
occurs  in  the  tissues  like  nervous tissues,  RBCs,  Retina,  Blood  
vessels  and  intestinal  mucosa.  In  liver,  glucose  uptake  is  
increased  indirectly  by  increasing  the  utilisation  of  glucose  not  by  
the  translocation  of  GLUT  proteins. 
In  liver: 
Insulin  facilitates  the  glucose  uptake  by  increasing  the  
glucokinase  action.  Glucokinase  increases  the  glucose  utilisation 
by  mediating  the  conversion  of  glucose  into  glucose  6  phosphate  
which  inturn  increases  the  glucose  uptake  via  GLUT-2  
transporter.  Insulin  induces  glycolysis  by  enhancing  the  activity  of  
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phospofructokinase  and  pyruvate  kinase  enzymes.  It  stimulates  
glycogen  synthesis  from  glucose  by  inducing  glycogen  synthase  
enzyme  complex  activity.  Then  this  glycogen  is  stored  in  the  
liver.  By  inhibiting  the  activity  of  glycogen  phosphorylase  and  
glucose  6  phosphatase  enzymes  it  inhibits  glycogenolysis.  It  also  
inhibits  gluconeogenesis  by  preventing  the  entry  of  gluconeogenic  
aminoacids  and  by  inhibiting  the  enzymes  pyruvate  kinase,  
phospoenol  pyruvate  carboxy  kinase  and  fructose  1,6  
bisphosphatase. 
In  adipose  tissue: 
Insulin  increases  the  glucose  uptake  by  promoting  the  
translocation  of  GLUT-4  to  the  cellmembrane.  Then  the  entered  
glucose  is  converted  into  α-glycerophosphate  which  is  used  in  the  
esterification  of  fattyacids.  By  this  process  esterified  fatty  acids  is  
stored  as  triglycerides. 
In  skeletal  muscle:  
Insulin  increases  the  glucose  uptake  by  promoting  the  
translocation  of  GLUT-4  to  the  cellmembrane.  Insulin  increases  
glucose  entry  by  10-20  folds  for  few  hours  after  meals.  During  
exercise,  muscle  membrane  permeability  to  glucose  increases   
even  in  the  absence  of  glucose.  Because  of  this,  the  diabetic  
44 
 
patients  are  advised  for  regular  exercise.  Insulin  facilitates  the  
muscle  glycolysis  by  stimulating  the  pyruvate  dehydrogenase  
activity.  It  also  promotes  storage  of  glucose  as  glycogen  in  the  
muscle  tissues. 
ON  FAT  METABOLISM: 
Insulin  facilitates  the  storage  of  fat  and  reduces  the  fatty  
acid  mobilisation  and  oxidation  by  following  mechanisms. 
In  adipose  tissue: 
Insulin  inhibits  lipolysis  by  inhibiting  the  enzyme  hormone  
sensitive  lipase.  By  preventing  lipolysis  and  further  release  of  
free  fatty  acids  into  the  circulation  insulin  reduces  the  formation  
of  ketoacids  in  the  liver.  So  insulin  is  considered  as  major  
“ANTIKETOGENIC  HORMONE”  in  the  body.   
Insulin  induces  the  lipogenesis  by  activating  the  enzyme  
Lipoprotein  lipase  which  is  present  in  the  vascular  endothelium.  
Triglycerides  and  VLDL  cholesterol  cannot  enter  the  adipose  
tissue  directly.  So  they  are  converted  into  free  fatty  acids  by  the  
lipoprotein  lipase ,  then  these  free  fatty  acids  enter  into  the  
adipose  tissue  where  they  are  modified  and  stored  as  
triglycerides.  
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In  Liver: 
Insulin  facilitates  the  synthesis  of  fatty  acids  from  glucose  
by  activating  the  enzyme  acetylcoA  carboxylase  which  mediates  
the  conversion  of  acetylcoA   to  malonylcoA  formation.  This  
malonylcoA  is  used  for  the synthesis  of  fatty  acids.  It  also  
stimulates  the  fatty  acid  synthase  complex.  In  the  HMP  shunt,  by  
promoting  the  action  of  glucose  6  phosphate  dehydrogenase  it  
increases  the  production  of  triphosphopyridines,  which  is  needed  
for  the  fatty  acid  synthesis.   
Insulin  facilitates  the  cholesterol  synthesis  from  acetylcoA  
by  stimulating  the  enzyme  HMGcoA  reductase.  Insulin  is  also  
helpful  in  the  usage  of  VLDL  and  LDL  proteins.  So  in  diabetic  
patients  in  the  absence  of  insulin  action  these   VLDL  and  LDL  
protein  level  in  blood   may  increase  and  they  are  involved  in  the  
pathogenesis  of  atherosclerosis. 
ON  PROTEIN  METABOLISM: 
Insulin  promotes  the  synthesis  of  proteins  in  the  muscle  
and  liver.  It  promotes  aminoacids  entry  into  the  muscle  tissues.  
By  stimulating  the  gene  transcription  and  translation  of  mRNA,  it  
stimulates  protein  synthesis  on  ribosomes.  By  reducing  the  
lysosomal  enzyme  activity,  insulin  inhibits  proteolysis.  In  liver,  
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insulin  retains  the  aminoacids  for  protein  synthesis  by  decreasing  
the  gluconeogenesis. 
Insulin  deficiency  in  diabetics  showed  drastic  reduction  in  
the  synthetic  rate  of  albumin  associated  with  significant  increase  
in  the  level  of  plasma  fibrinogen 2. 
GLUCAGON57 
29  aminoacids  containing  protein  hormone  secreted  by  the  
α  cells  of  pancreatic  islets.  It  is  the  “PRIMARY  COUNTER  
REGULATORY  HORMONE”  responsible  for  increasing  the  
blood  glucose  concentration.  It  increases  the  blood  glucose  level  
by  increasing  the  gluconeogenesis  and  glycogenolysis  in  the  liver.  
It also decreases glycolysis and lipogenesis from  glucose  in  the  liver. 
 
 
PATHOPHYSIOLOGY  OF  TYPE  II  DIABETES  MELLITUS  
Pathophysiology  of  type  II  diabetes  is  complex  and  is  in  
association  with  the  involvement  of  environmental  factors  and  
genetic  factors56.   
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Genetic  association  of  type  II  diabetes: 
 Type  II  diabetes  has  strong  genetic  susceptibility  factor.  
Risk  of  getting  diabetes  is  about  40%  if  both  parents  having  
type  II  diabetes.  The  chance  of  getting  type  II  diabetes  in  
identical  twins  is  around  70-90%.     
 It  is  a  polygenic  form  of  disease  with  involvement  of  more  
than  20  genes.  Some  of  the examples  for  genetic  polymorphism  
are  mutations  present  in  the  genes  encoding  the  proteins  like  
PPAR-γ,  K+ATP  channel,  Zinc  transporter,  insulin  receptor  
substrate  protein  and  calcium  dependent  cysteine  protease  
(calpain-10) 1. 
THE  THREE  CLASSICAL  ABNORMALITIES  OF  TYPE  II  
DIABETES  INCLUDE, 
 Insulin  resistance 
 Impaired  insulin  secretion  by  the  β  cells 
 Increased  glucose  production  by  the  liver  
INSULIN  RESISTANCE55 
It  is  defined  as  decreased  sensitivity  of  target  tissues  like  
skeletal  muscle  and  adipose  tissue  to  the  insulin  which  is  the  
predominant  abnormality  in  type  II  diabetes  mellitus1. 
  
 
TYPE 2 DIABETES: INSULIN RESISTANCE 
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Historical  aspects  of  Insulin  Resistance: 
 Gerald ‘M’ reaven  was the  person  who  first  described  about  
metabolic  syndrome  and  he  said  that  obesity  and  reduced  
physical  activity  each  one  is  responsible  for  nearly  25%  of  
insulin  resistance  and  another  50%  is  by  genetic  factors. 
In  1936,  Himsworth  was  the  first  person  who  described  
that  hyperglycemia  in  some  diabetic  patients  is  because  of  
reduced  insulin  sensitivity  in  the  target  tissues  other  than  insulin  
deficiency. 
Genetic  Factors  include  mutation  of  genes  encoding ,  
Insulin  receptor  substrate  1 & 2 
Phosphatidyl  inositol  3  kinase 
GLUT  transporter  proteins 
Liver  glucokinase  promoter  gene 
Environmental  Factors: 
It  is  considered  as  the  major  contributor  of  insulin  
resistance.  It      includes  obesity,  reduced  physical  activity  and   
nutritional  factors.   
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Obesity: 
Central  obesity  is  the  most  powerful  risk  factor  of  diabetes.  
Not  only  the  increase  in  quantity  of  adipose  tissue  and  also  the  
adipose  tissue  dysfunction   is   responsible  for  Insulin  resistance.  
Central  adipocyte  is  more  lipolytic  than  the  adipocytes  of  
peripheral  tissues  and  releases   more  amount  of  non  esterified  
fatty  acids  into  circulation.  These  NEFA  gets  accumulated  in  the  
liver  and  skeletal  muscle  and  reduces  the  insulin  sensitivity  by  
causing  phosphorylation  of  serine  residue  instead  of  tyrosine  
residue  at  insulin  receptor  substrate  proteins.   
Central  adiposity  leads  to  increased  release  of  adipokines  
like  resistin,  retinol  binding  protein-4  and decreased  release  of  
adiponectin  and  leptin  into  circulation.  Resistin  is  the  hormone  
responsible  for  insulin  resistance.  Normally  leptin  and  adiponectin  
increases  the  insulin  sensitivity  by  stimulating  the  AMP  activated  
protein  kinase  enzyme  action.  This  enzyme  in turn  promotes  
fattyacid  oxidation  in  the  liver  and  skeletal  muscle.  Increased  
resistin  and  decreased  adiponectin  together  decreases  the  insulin  
sensitivity  in  target  tissues31.   
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Reduced  physical  activity: 
Urbanisation  of  the  country  has  lead  to  reduced  physical  
activity.  It  is  the  another  factor  responsible  for  more  prevalence  
of  diabetes  among  urban  people  than  in  the  rural  one. 
Nutritional  factors: 
Nutritional  factors  like  excess  calorie  intake  in  the  form  of  
high  carbohydrate  diets  like  refined  flour,  pasta,  raw  rice,  aerated  
soft  drinks,  sweet,  sugar  leads  to  type  2  diabetes.  Also  the  intake  
of  high  saturated  fat  diets  like  coconut  oil,  vanaspathi,  omega6  
fatty  acid  rich  foods  like  corn  and  decreased  intake  of   
vegetables  and  fruits.  Dietary  deficiency  of  chromium,  zinc,  
selenium  and  also  vitamin  D  deficiency  can  lead  to  diabetes. 
INSULIN  RESISTANCE  ASSOCIATED  METABOLIC  
ABNORMALITIES : 
Decreased  glucose  utilisation  by  the  target  organs  like  
adipose  tissues  and  skeletal  muscles  is   due  to  reduced  insulin  
sensitivity  .  Increased  gluconeogenesis  in  the  liver  leading  to  
entry  of  more  glucose  into  the  blood  which  finally  results  in  
hyperglycemia.  Increased  hepatic  gluconeogenesis  is  responsible  
for  increase  in  fasting  plasma  glucose  concentration  whereas  
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decreased  peripheral  utilisation  of  glucose  is  responsible  for  
postprandial  hyperglycemia  in  diabetes  mellitus.  
 In  skeletal  muscles  and  liver,  the  glycogen  storage  is   also  
affected.  In  adipose  tissue,  increased  lipolysis  leading  to  release  
of  more  free  fatty  acids  into  circulation  results  in  increased  
content  of  VLDL  proteins  and  triglycerides  in  the  blood1. 
 
IMPAIREMENT  OF  INSULIN  SECRETION 55 
It  occurs  due  to  progressive  β  cell  dysfunction  with  
decrease  in  β  cell  mass. 
Phase  I: Increase  in  the  β  cell  mass  to  overcome  the  insulin   
resistance  leads  to  hyperinsulinemia. 
Phase  II:  (stage  of  prediabetes)  It  is  the  early  stage  of  β  cell  
dysfunction.  In  this  phase  glucose  induced    β  cell  response  is  
affected.  But  response  to  other  stimulants  remains  normal. 
Phase  III:  In  this  phase   there  is  a  gross   reduction  in  the  
response  of  β  cells  to  glucose  stimulus  along  with  decrease  in  
response  to  other  secretogogues. 
Phase  IV:  There  is  absence  of  β  cell  proliferation  in  this  phase.  
This  is  because  of  chronic  hyperglycemia  which  results  in  40-
50%  reduction  in  the  β  cell  mass. 
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COMPLICATIONS  OF  TYPE  II  DIABETES1 
 
ACUTE  COMPLICATIONS: 
 Diabetic  ketoacidosis 
 Hyperglycaemic  hyperosmolar  state. 
 
CHRONIC  COMPLICATIONS: 
 
 MICROVASCULAR  DISEASES: 
o Retinopathy   
o Neuropathy – sensory,  motor,  autonomic. 
o Nephropathy 
 
 MACROVASCULAR  DISEASES: 
o Coronary  artery  disease  (CAD) 
o Peripheral  arterial  disease (PAD) 
o Cerebrovascular  disease. 
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Chronic  complications  like  microvascular  and  macrovascular  
complications  are  responsible  for  most  of  the  diabetes  associated  
morbidity  and  mortality.  Regarding  macrovascular  diseases,  the  
occurrence  of  coronary  artery  diseases  and  associated  mortality  
risk  is  2-4  times  higher  in  type  II  diabetic  patients.  Multiple  
factors  are  involved  in  the  pathogenesis  of  macrovascular  diseases  
and  these  are  chronic  hyperglycemia,  hypercholesterolemia,  and  
Systemic  hypertension.  But  the  central  mediator  of  this  
pathogenesis   is  the  glucotoxicity.   
 
 
THEORIES  OF  COMPLICATIONS: 1,31 
1st  theory  said  that  advanced  glycation  end  products (AGE)  
like  glyoxal,  methyl  glyoxal  and  3-deoxy  glucosone  are  formed  
by  raised  intracellular  glucose. Then  these  AGEs  bind  with  
receptor  called  RAGE (Receptor  of  advanced  glycation  end  
products)  present  on  the  macrophages,  endothelium  and  vascular  
smooth  muscle  by  non  enzymatic  glycosylation  of  both  intra  and  
extracellular  proteins.  
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Advanced  glycation  end  products- Receptor  of  Advanced  
glycation  end  products  complex  in  the  blood  vessels  causes  
production   of  oxygen  free  radicals    in  the  endothelium,  which   
enhances  the  procoagulant  action  on  endothelial  membrane  of  the  
blood  vessel.   
AGEs  can  also  cause  cross  linking  of  extracellular  matrix  
proteins.  Cross  linking  of  type  I  collagen  in  large  blood  vessels  
leads  to  decreased  elasticity  and  endothelial  injury.  Cross  linking  
increases  protein  deposition  leading  to  accumulation  of  more  and  
more  LDL  proteins  in  the  tunica  intima  of  large  vessel  walls  
accelerating  the  atherogenesis.  
The  2nd  theory  proposed  that,  in  case  of  excess  intracellular  
glucose,  some  amount  of  glucose  is  metabolised  into  sorbitol   by  
the  enzyme  aldose  reductase  .  Increased  sorbitol  induces  oxygen  
free  radicals  formation  which  inturn  causes  cellular  dysfunction. 
The  3rd  theory  said  that,  increase  in  production  of  diacyl  
glycerol  causes  activation  of  Protein  kinase – C.  The  activated  
Protein  kinase – C   induces  the  production  of  plasminogen  
activator  inhibitor-1  which   inhibits   fibrinolysis.  It  will  also  
promote  the  formation  of  vascular  endothelial  growth  factor-1  
leading  to  neovascularisation.   Protein kinase –c  activation  is    
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associated  with  decreased  expression  of  eNOS  leading  to  
decreased  nitric  oxide  level  which  also  accelerates  endothelial 
injury. 
 
GLYCOSYLATED  HEMOGLOBIN55 
In  present  days,  HbA1c  is  considered  as  s  best  tool  for  
assessing  the  long  term  glycemic  control  in  diabetic  patients. 
HISTORICAL  REVIEW: 
In  1955,  Kunkel  and  his  co workers  observed  that  the  
haemoglobin  consists  of  fast  and  slow  moving  components  of  
electrophoresis. 
Rahbar  found  that,  the  fast  components  of  haemoglobin  
was  elevated  in  diabetics  with  poor  metabolic  control. 
Bunn  and  Nathan  described  about  the  clinical  correlation  of  
HbA1c.  Goldstein   studied  the  kinetics  of  HbA1c. 
PROCESS  OF  GLYCOSYLATION: 
It  occurs  by  binding  of  glucose  with  β  chain  of  HbA  at  its  
amino  terminal  valine.  This  will  alter  the  pattern  of  movement  in  
cation  exchange  chromatography  and  is  the  major  glycosylated  
haemoglobin  called  HbA1c .  Normal  value  is  4 - 6%.   
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The  life  span  of   RBC  is  about  120 days,  during  which  
haemoglobin  gets  attached  with  glucose  molecule  to  from  
glycosylated  haemoglobin. In diabetes  mellitus  patients  with  poor  
glycemic  control, the  quantity  of  glycosylated  haemoglobin  is  in  
increased  amount  when  compared to  patients  with  good  glycemic  
control61. 
IMPORTANCE  OF  GLYCEMIC  CONTROL: 
In  diabetes  mellitus,  management  of  the  disease  is  mainly  
focussed  on  prevention  of  chronic  complications  and  to  interfere  
with the   progression  of  disease.   
The  United  kingdom  prospective  diabetes  (UKPDS)  study  
established  the  relationship  between  good  glycemic  control  and  
prevention  of  complications  in  type  II  diabetes  mellitus.  
The  American  diabetes  association  recommended  HbA1c  
level  of  <7%  as  a  goal  for  good  glycemic  control  in  diabetic  
patients1.  
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DIABETES   -   PROTHROMBOTIC  STATE62 
Endothelial  dysfunction:  
Vascular  endothelium  acts  as  a  physical  barrier  between  
blood  and  vessel  wall.  It  is  also  essential  for  maintaining the   
balance  between  procoagulant  and  anticoagulant  system  of  blood.  
Smooth  surface  of  endothelium  prevents  the  platelet  adhesion,  
aggregation  and  blood  coagulation,  whereas  induces  the  
fibrinolysis. 
In  diabetes  mellitus,  irreversible  glycation  of  subendothelial  
collagen  and  structural  proteins  forms  the  AGEs.  These  glycation  
end  products  produce  alterations  in  the  basement  membrane  
structure  leading  to  endothelial  injury  and  increased  vascular  
permeability.   
vWF  is  a  multimeric  protein  synthesised  and  stored  within  
the  weibel  palade  bodies  present  in  the  endothelium  of  blood  
vessels.  During  endothelial  injury,  vWF  released  into  circulation  
leading  to  hypercoagulablity  of  the  plasma.  Positive  correlation  is  
observed  between  increased  vWF  and  vascular  complications  of  
type  II  diabetes  mellitus. 
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Changes  in  platelets: 
Glycation  of  platelet  membrane  proteins  is  associated  with  
change  in  the  shape  of  platelets,  reduced  membrane  fluidity,  
increased  platelet  activation,  increase  in  number  of  GP Ib  and  
GPIIb-IIIa  receptor  complexes  finally  leading  to  platelet  plug  
formation.   
Changes  in  clotting  factors: 
Fibrinogen  is  an  acute  phase  protein  which  gets  elevated  in  
type  II  diabetes  mellitus  patients  and  is  considered  as  an  
independent  risk  factor  for  cardiovascular  diseases.  Glycation  of  
fibrinogen  molecule  leading  to  formation  of  dense  fibrin  clot  with  
fine  fibres  which  are  less  sensitive  to  fibrinolysis.  Glycated  fibrin  
binds  with  t-PA  and  plasminogen  in  lesser  amount,  but  binds  to  
α2  antiplasmin  more  avidly  leading  to  production  of  less  plasmin.  
This  in  turn  is  responsible  for  impaired  fibrinolysis63. 
Diabetes  associated  dyslipidemia  increases  clotting  factor  
VII (FVII)  in  the  blood.  Normally,  part  of  FVII  is  bound  to  
triglyceride - rich  VLDL.  Because  of  increased  VLDL  content  in  
diabetes,  FVII  in  the  plasma  increases  along  with  lengthening  of  
half  life  of  FVII. 
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Factor  VIII/ vWF  complex  is  also  increased  in  type  II  
diabetes , because  of  endothelial  injury  and  inflammation  
associated  increase  in  vWF.   Half  life  of  vWF  bound  F VIII  is  
increased  from  37  minutes  to  24.5  hrs. 
Changes  in  fibrinolysis60 
Fibrinolysis  is  a  naturally  existing  mechanism,  which  
prevents  the  spread  of  blood  clot  away  from  the  site  of  injury  
by  causing  dissolution  of  blood  clot.  Plasmin  or  fibrinolysin  is  
the  active  substance  involved  in  fibrinolysis 25,28.   
Plasmin  is  a  serine  protease  enzyme  present  in  the  plasma,  
which  cleaves  lysine  residues  and  arginine  residues  at  all  the  
sites  in  fibrin  and  fibrinogen.  Then  fibrin  molecules  are  lysed  
and  broken  down  to  form  small  soluble  substances  called  fibrin  
degradation  products.   
Plasminogen  Activators :  
These  are  serine  protease  enzymes  present  in  the  plasma.  
They  cleave  single  covalent  disulfide  bond  from  the  inactive  
precursor  plasminogen  and  converts  it  into  active  substance  called  
plasmin.  The  two  different  plasminogen  activators  are  t-PA  and  
u-PA.   The  t-PA  is  secreted  by  endothelial  cells  whereas  u-PA  is  
secreted  by  endothelial  cells,  monocyte  and   fibroblasts.  Fibrin  
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deposited  at  the  site  of  vessel  injury  and  circulating  epinephrine    
act  as  stimulants  for  the  release  of  t-PA.  Single  chain  t-PA  and  
u-PA  initiate  fibrinolysis  through  their  synergistic  action.   
Single  chain  u-PA  acts  on  fibrin  bound  plasminogen  and  
converts  it  into  plasmin.  Plasmin  removes  the  peptide  bonds  
present  at  carboxy  terminal  of  fibrin  and  exposes  other  carboxy  
terminal  lysine  residues,  by  which  plasmin  cleaves  subsequent  
peptide  bonds  and  forms  fibrin  degradation  products.  
 
Fibrin  Degradation  Products : 
Plasmin  cleaves  the  peptide  bonds  present  in  the  fibrinogen  
or  fibrin  in  a  sequence  and  forms  large  degradation  products  
called  X  and  Y  and  smaller  degradation  products  called  D  and  
E.   Large  degradation  products  inhibit  fibrin  polymerisation  
whereas  X,Y  and  D  fragments  inhibit  binding  of  fibrinogen  to  
GPIIb-IIIa  receptors,  hence  prevent  platelet  aggregation. 
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Plasminogen  activator  inhibitors:   
These  substances  play  a  major  role  in  fibrinolysis  
regulation  process.  There  are  two  types,  PAI-1  and  PAI-2.  PAI-1  
is  secreted  by  the  endothelial  cells  and  also stored  in  the  α-
granules  of  platelets.  PAI-1  inhibits  both  t-PA  and  u-PA.  PAI-2  
is mainly secreted by the placental macrophages and inactivates  u-PA.   
Increased  PAI-1 in  diabetes :     
In  type  II  diabetes,  elevated  levels  of  PAI-1  inhibits  t-PA  
and  u-PA  leading  to  decreased  production  of  plasmin  and  
impaired  fibrinolysis.   PAI-1  levels  show  circadian  changes  with  
maximum  levels  in  the  morning  and  this  is  responsible  for  the  
increased  incidence  of  acute  myocardial  infarction  in  the  morning. 
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Hypercoagulability  is  associated  with  impaired  fibrinolysis  
leading  on  to  procoagulant  state  in  diabetes.  Glycation  of  
fibrinogen  results  in  alteration  in  the  structure  of  formed  clot  
with  less  susceptibility  to  clot  lysis.  This  is  because,  thin  fibrin  
fibers  of  modified  clot  bind  less  avidly  to  plasminogen  and  tPA  
whereas  bind  more  avidly  with  antiplasmin63.  
 
STUDIES  RELATED  TO  FIBRINOGEN  AND   
DIABETES  MELLITUS 
A  cross  sectional  study  done  among  1574  type  II  diabetes  
mellitus  patients  by  Bruno  G  et  al  observed  the  high  prevalence  
of  hyperfibrinogenemia  in  diabetes  and  plasma  fibrinogen  level  
was  significantly  associated  with  HbA1c  value 65. 
In  another  cross  sectional  study  done  by  Taj  Muhammad  
Khan  and  his  co-workers  found,  significantly  high  plasma  
fibrinogen  level  and  increased  plasma  viscosity  in  diabetic  
patients. They  also  observed  significantly  increased  plasma  
fibrinogen  level  in  diabetics  with  complications 66. 
Nizar  and  Elshazali  described  that  plasma  fibrinogen  level  
was  increased  in  type  II  diabetes  mellitus  patients  than  in  
controls, but it was in the  higher  limit  of  normal  range  (3.96±0.92).  
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The  mean  plasma  fibrinogen  level  was  slightly  increased  in  
diabetic  patients  with  poor  glycemic  control  than  in  patients  with  
good  glycemic  control 67. 
In  the  study  of  A.S. Bembde,  plasma  fibrinogen  level  was  
significantly  increased  in  type  II  diabetic  patients  when  compared  
to  healthy  subjects.  Plasma  fibrinogen  level  was  also  associated  
with  other  cardiovascular  risk  factors  like  systemic  hypertension,  
obesity  and  smoking.  Diabetic  patients  with  poor  glycemic  control  
had  higher  mean  plasma  fibrinogen  level.  Plasma  fibrinogen  
levels  were  positively  correlated  with  glycosylated  haemoglobin  
level68.   
In  another  cross  sectional  study  conducted  at  Tribhuvan  
university  teaching  hospital   by  Dr  Kafle  et  al  found,  significantly  
higher  plasma  fibrinogen  level  in  type  2  diabetic  patients. They  
also  observed  that  plasma  fibrinogen  level  was  significantly  
correlated  with  glycosylated  haemoglobin69. 
Antonio  cereillo  et  al  observed  significantly  increased  
plasma  fibrinogen  level  in  diabetics.  Plasma  fibrinogen  in  
diabetics  was  positively  correlated  with  thrombin  activation  
parameters  and  suggested  that    fibrinogen  might  be  a  
cardiovascular  risk  factor  in  diabetes  mellitus  patients 70. 
64 
 
 Ying  Zhao  and  co-workers  found  significantly  reduced 
activated  partial  thromboplastin  time  and  elevated  plasma  
fibrinogen  level  in  diabetic  subjects.  Significant  changes  in  the  
above  parameters  were  also  observed  in  persons  with  impaired  
fasting  glucose  when  compared  to  normoglycemic  subjects71. 
In  the  study  of  Ritu  Madan  et  al,  significantly  increased  
levels  of  PAI-1,  plasma  fibrinogen  and  vWF  activity  were  
observed  in  diabetic  patients  when  compared  to  healthy  control  
group.  They  said  that  diabetes  is  a  hypercoagulable  state  which  
contributes  to  the  cardiovascular  complications  of  diabetes  
mellitus72. 
In  the  Framingham off spring study done by  James J.Stec et al,  
increased  plasma  fibrinogen  level  correlated  with  conventional  
cardiovascular  risk  factors  like  diabetes  mellitus,  systemic  
hypertension ,  smoking  and  dyslipidemia17. 
According  to  Venkataramana.G  et  al,  in  type  II  diabetes  
mellitus,  total  proteins  as  well as  fibrinogen  was  significantly  
increased  whereas  serum  albumin  was  significantly  decreased  than  
in  control  group.  They  said  that,  this  increased  fibrinogen  may  
also  be  due  to  increased  plasma  glucose in  diabetes 73. 
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Rocco  Barazonni  and  co-workers  found  that,  on  exogenous  
insulin  infusion,  plasma  fibrinogen  concentration  was  increased  
because  of   increase  in  both  fractional  and   absolute  synthetic  rate  
by  41%  and  43%  respectively74. 
In  a  study  done  by  P  De  Feo  et  al,  insulin  deficiency  in  
diabetic  patients  was  associated  with  50%  increase  in  fibrinogen  
synthesis  and  29%  decrease  in  albumin  synthesis  with  p value  of 
<0.03.  They  said  that,  increased  plasma  fibrinogen  level  was  due  
to  insulin  deficiency  associated  metabolic  stress  on  the  liver18. 
In  the  study  of  Danuta  Milosz  et  al,  mean  Plasma  
Fibrinogen  level  was  significantly  elevated  in  diabetics  with  
severe  coronary  atherosclerosis  with  the  p  value  of  <0.05 75. 
Rodolfo  Guardado-Mendoza  et  al  said  that,  fibrinogen  is  
the  strong  predictor  of  silent  myocardial  ischemia  and  it  should  
be  included  in  the  cardiovascular  risk  profile  of  diabetic  patients.  
They  were  also  found  a  significant  correlation  between  plasma  
fibrinogen  and  glycosylated  haemoglobin76. 
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MATERIALS AND METHODS 
STUDY DESIGN: 
This  is  a  cross-sectional  study.  
STUDY  PLACE:     
The  study  was  carried  out   in  the   department  of  
Physiology,  in  association  with  department  of  Diabetology, 
Coimbatore  Medical  College  Hospital,  Coimbatore. 
STUDY PERIOD: 
 The study was conducted from August 2013  to  June 2014. 
INCLUSION  CRITERIA: 
 Age  and  sex  matched  healthy  individuals  taken  as  control  
group  in  the  study. 
 Type  II  diabetic  patients  of  both  sexes  in  the  age  of  40-60  
years.   
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EXCLUSION  CRITERIA: 
Patients  with  history  of, 
 Type  I  diabetes  mellitus  
 Hypertension 
 Smoking 
 Obesity 
 Coagulation  disorders 
 Recent  surgery 
 Drug  intake  -  Oral  contraceptive  pills 
 Anticoagulants  like  Heparin,  Warfarin. 
 Renal  diseases 
 Liver  diseases 
 Pregnancy 
 Postmenopausal  state 
 Infectious  diseases   
 Inflammatory  conditions  
 Hypercholesterolemia 
 Vascular  complications  of  Diabetes  mellitus  
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STUDY  SUBJECTS: 
After  fulfilling  all  the  inclusion  and  exclusion  criteria,  150   
subjects  were  selected  for  the  present  study.  The  sample  
population  was  grouped  into  type  II  diabetes  mellitus  patients  
(75)  and  control  group  (75).  Subjects  in  control  group   were  
healthy  volunteers  accompanying  the  patients.   
Materials  used  for  the  study: 
1. Proforma :    To   obtain   detailed   history,  to  record  the   vital  
parameters   and  to  measure  the  anthropometric  indices. 
2. Portable  weighing  machine – to  record   the  body   weight   in  
kilograms. 
3. Stadiometer – to   measure   the   standing   height   in  
centimeters. 
4. Standardized    mercury   sphygmomanometer – to   record   the  
Blood  Pressure. 
5. Quantimate  turbidimetry  analyser – To  measure  plasma   
fibrinogen,  glycosylated  haemoglobin  (HbA1c) . 
6. Auto  analyser –   Random  blood  sugar 
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Methodology: 
 After  obtaining  clearance  from  the  institutional  ethical  
committee,  the  subjects  were  selected  and  grouped.  
The  subjects  were  explained  about  procedure  in  detail  
and  informed  consent  was  obtained. 
I) History  taking  and  clinical  examination: 
 Detailed   history   was   elicited   from  the  subjects   to  
rule  out  signs  and  symptoms  of    hypertension,  
cardiovascular  diseases,  liver  and  kidney   diseases   
and  other  causes  influencing  plasma  fibrinogen   level. 
 A  thorough  clinical  examination  of  all  systems  of  
body  was  done. 
II) Measurement  of  anthropometric  indices: 
a) Weight  of  subject:  The   subjects   were   asked  to  stand   
erect    with  their  arms  relaxed    at  their  side,  with  both  
feet  close  together.   By   using  a  portable  standard  
weighing   machine,  weight  in  kilograms   was   recorded . 
  
COLLECTION  OF  BLOOD  SAMPLE 
 
 
 
 
 
 
 
 
 
 
 
ANTICOAGULANT  ADDED  CONTAINERS 
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b) Height  of  subject:  By   using   a   stadiometer ,  height  of  
subject  in   centimetres   was    measured  by   asking  the  
subject    to  stand   erect   and  the   vertical   height   was  
measured. 
c)  BMI  of  subject:  Body  mass  index    was  calculated   by  
using quetelet’s  index.    
BMI =   Weight ( Kg) /  Height2 (m) 
III) Measurement   of  Blood  Pressure: 
First,  the  subjects  were  asked  to  sit  quietly   for  15  minutes  
in   a   quiet   room  with  comfortable  room  temperature.  Then  
blood   pressure   was   recorded   in   all   subjects   by  using  a  
standard  sphygmomanometer having a  cuff  size  of   25  x  12.5  cms.  
IV)  Blood  investigation:   
 Median  cubital  vein  in  the  front  of   forearm    was   selected  
for   venous  blood  collection.   The  skin  over  the  vein  was   
cleaned  with   spirit  and  cotton  swab  and  allowed  to  dry.  Then  a  
disposable   sterile  needle  fitted   with  10  ml  syringe   was   
introduced   in  to  the  vein   and   4ml  of  blood  was  collected  and  
poured  into  separate  containers  having  different  anticoagulants.   
  
TURBIDIMETRY 
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3.2%  sodium  citrate  anticoagulant  added  blood  was  used  
for  measuring  plasma  fibrinogen  and  random  blood  sugar. 
The  anticoagulant   EDTA  (Ethelyne  Diamine  Tetra  Acetic  
acid)  mixed  whole  blood  is  used  for  measuring  glycosylated  
haemoglobin  (HbA1c). 
METHODS  OF  MEASUREMENT: 
1. Turbidimetric  immunoassay  : 
Plasma  fibrinogen   
Glycosylated  haemoglobin  (HbA1c)   
2. Glucose  oxidase-peroxidase  method : 
Random  blood  sugar   
 
TURBIDIMETRIC  IMMUNOASSAY 
Measurement  of  Plasma  fibrinogen 
Reagents  used: 
R1  -  activation  buffer 
R2  -  anti  fibrinogen  antibody   
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Principle: 
The  method  is  based  on  aaglutination  reaction.  Reagent  R1  
and  R2  are  added  to  test  sample.  Fibrinogen  present  in  the  test  
sample  react  with  anti  fibrinogen  antibody  and  forms  insoluble  
complex  with  increasing  turbidity.  Increase  in  turbidity  depends  
on  concentration  of  fibrinogen  in  the  test  sample  and  it  was  
measured  at  340nm. 
Specimen  collection  and  preparation: 
Freshly  collected  blood  was  added  with  3.2%  sodium  
citrate  solution  and  centrifuged  immediately  for  5minutes  at  
3000rpm.then  plasma  was  separated  and  transferred  into  a  clean  
micropipette. 
Test  procedure: 
Test  specimen  was  diluted  with  normal  saline  in  the  ratio  
of  1:10.  Then  0.5ml  of  activation  buffer  and  0.02ml  of  test  
sample  were  added  and  mixed  thoroughly  in  the  cuvette  then  the  
mixure  was  incubated  at  37 0 C  for  5minutes. Immediately  
absorbance  (A1)  was  read.  In  the  next  step,  0.1ml  of  anti  
fibrinogen  antibody  was  added  and  absorbance  (A2)  was  read  at  
the  end  of  5minutes. ∆A  (A2-A1)  was  calculated  for  test  sample.  
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Then  the  test  was  carried  out  with  different  dilution  of  test  
sample  such  as,  1:20,  1:40,  1:60.  ∆A  of  diluted  test  sample  was  
interpolated  on  the  calibration  curve  and  fibrinogen  concentration  
was  measured. 
 
Measurement  of  glycosylated  haemoglobin  (HbA1c) 
Reagents  used: 
R1  -  latex  particles 
R2  -  mouse  antiHbA1c  antibody  solution  
R3  -  Goat  antimouse  human  IgG  antibody  solution 
Quantia  hemolysing  reagent  solution.    
Principle: 
Immunoassay  method  is  based  on  agglutination  reaction.  
After  adding  hemolysing  solution,  test  sample  is  allowed  to  react  
with  latex  Reagent  (R1).  The  amount  of  binding  depends  on  
relative  concentration  of  HbA1c  in  the  blood.  Then  the  mixure  is  
allowed  to  react  with  mouse  antiHbA1c  antibody  reagent  (R2),  
wherein  R2  bind  to  latex  bound  HbA1c  molecules.  Goat  
antimouse  human  IgG  antibody  (R3)  binds  with  HbA1c-R2  
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complex  by  agglutination  reaction  and  it  should  be  measured  at  
630nm.  Change  in  turbidity  of  sample  depends  on  concentration  
of  HbA1c  in  the  sample. 
Test  sample  preparation: 
Blood  sample  was  thoroughly  mixed  for  the  uniform  
distribution  of  red  blood  cells.  Then  0.5ml  of  hemolysing  agent  
was  added  with  0.01ml  of  test  sample  and  and  which  was  mixed  
well  and  wait  for  15  minutes  for  complete  hemolysis.  Hemolysed  
sample  is  called  as  lysate.   
Test  procedure: 
0.4ml  of  latex  particle  (R1)  was  taken  in  a  measuring  
couvette.  Then  0.01ml  of  lysate  was  added  with  R1  and  it  was  
incubated  at  37 0C  for  2  minutes.  After  adding  of  0.1ml  of  
mouse  antiHbA1c  antibody  reagent  (R2),  solution  was  thoroughly  
mixed  and  again  incubated  for  3  minutes.  Then  0.02ml  of  Goat  
antimouse  human  IgG  antibody  reagent  (R3)  was  added  and 
solution  was  gently  mixed.   
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The  absorbance  A1  was  read  at  10  seconds  and  absorbance  
A2  was  read  at  the  end  of  2  minutes.  ∆A  (A2-A1) was  
calculated  for  test  sample  and  calibration  curve  was  plotted  
against  %HbA1c  and  concentration  of  HbA1c  for  test sample  was  
measured. 
 
 
GLUCOSE  OXIDASE-PEROXIDASE  METHOD 
(TRINDER’S  METHOD) 
Measurement  of  Random  Blood  Sugar 
Glucose  present  in  the  test  sample  was  oxidised  to  produce  
gluconic  acid  and  hydrogen  peroxide  in  the  presence  of  glucose  
oxidase  enzyme.  Then  the  enzyme  peroxidise  promotes  the  
reaction  between  4-aminoantipyrine  and  phenol  to  yield  
quinoneimine  dye  complex.  absorbance  was  read  and  which  was  
correspond  to  the  glucose  concentration  in  the  test  sample. 
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After  thorough  clinical  examination  and  blood  investigations  
study  population  were  divided  into  two  groups  and  categorised as, 
Group  I  -   75  Type II  diabetes  mellitus  patients 
Group  I A  -   Type II  diabetes  mellitus  patients  with                
                                     HbA1c   ≤ 7%  (good  glycemic  control)   
Group  I A1  -    diabetes  mellitus  with  duration  of                        
                                    less  than  5  years 
Group  I A2  -    diabetes  mellitus  with  duration  of                                
                                    more  than  5  years 
Group  I B  -   Type II  diabetic  patients  with   
                                    HbA1c>7%  (poor  glycemic  control )  
Group  I B1  -   diabetes  mellitus  with  duration  of                                 
                                    less  than  5  years 
Group  I B2  -   diabetes  mellitus  with  duration  of                                        
                                    more  than  5  years 
Group  II  -   75  age  and  sex  matched  healthy   
                                    individuals  as  controls. 
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STATISTICAL  ANALYSIS 
 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta.  
 Using this software, range, frequencies, percentages, means, 
standard deviations, chi square, and  'p'  value  were calculated. 
Unpaired  ‘t’  test was used to test the significance of difference 
between quantitative variables and Yate’s and Fisher’s chi square tests 
for qualitative variables. A 'p' value less than 0.05 is taken to denote 
significant relationship. Correlation coefficient was calculated using 
Excel software. A value greater than + 0.5 is taken to indicate the 
existence of correlation between the variables.   
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RESULTS 
Study  subjects  of  both  sexes  were  divided  into  two  groups  
and  categorized  as: 
Group  I  -   75  Type II  diabetes  mellitus  patients 
Group  I A  -   37  Type II  diabetes  mellitus  patients  with                
                                     HbA1c   ≤ 7%  (good  glycemic  control)   
Group  I A1  -    diabetes  mellitus  with  duration  of                        
                                    less  than  5  years 
Group  I A2  -    diabetes  mellitus  with  duration  of                                
                                    more  than  5  years 
Group  I B  -    38  Type II  diabetic  patients  with   
                                    HbA1c>7%  (poor  glycemic  control )  
Group  I B1  -   diabetes  mellitus  with  duration  of                                 
                                    less  than  5  years 
Group  I B2  -   diabetes  mellitus  with  duration  of                                        
                                    more  than  5  years 
Group  II  -   75  age  and  sex  matched  healthy   
                                    individuals  as  controls. 
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TABLE 1:COMPARISION  OF  HEIGHT ,WEIGHT  AND  BMI   
                  BETWEEN  GROUP  I  AND  GROUP  II 
Group 
Height Weight BMI 
Mean SD Mean SD Mean SD 
Study group 157.1 6.2 61.7 6.1 24.9 1.5 
Control 
Group 155.6 6.4 60.6 6.3 25.2 2.0 
‘p’ 0.1331  Not significant 
0.3051  
Not significant 
0.2768  
Not Significant 
There  is  no  statistical  difference  in  Height, weight  and  BMI  
between  study  group  and  control  group  and  the  groups  were  
comparable. 
FIGURE 1: 
 
80 
 
TABLE 2 : COMPARISION  OF  BLOOD  PRESSURE  
BETWEEN GROUP I  AND  GROUP II 
There  is  no  statistical  difference  in  blood  pressure  between  study  
group  and  control  group  and  the  groups  were  comparable. 
FIGURE  2: 
 
 
 
 
 
 
 
 
Group 
Systolic BP Diastolic BP 
Mean SD Mean SD 
GROUP I 112.2 6.8 73.6 4.1 
GROUP II 114.7 5.2 75.0 4.3 
‘p’ 0.112 Not significant 0.0663 Not Significant 
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TABLE 3: COMPARISION  OF  PLASMA FIBRINOGEN LEVEL     
                   BETWEEN  GROUP  I  AND  GROUP  II 
GROUP   
Plasma Fibrinagen (mgs / dl) 
Mean SD 
GROUP  I 276.6 87.9 
GROUP  II 160.3 49.7 
‘p’ <0.0001 Significant 
Statistically  significant  difference  was  present  between  study  group  and  
control  group. 
FIGURE 3: 
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TABLE 4:  COMPARISION  OF  PLASMA FIBRINOGEN LEVEL     
                   BETWEEN  GROUP  IA1  AND  GROUP  IA2 
Group 
Plasma Fibrinogen (mgs / dl) 
Mean SD 
Group IA1 s 202.7  58.2 
 Group IA2 235.3 36.4 
‘p’ 0.0641 Not significant 
Plasma  fibrinogen  level  increased  in  patients  with  more  than  5  
years  duration  than  in  patients  with  less  than  5  years  duration. 
 
FIGURE 4: 
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TABLE 5: COMPARISION  OF  PLASMA FIBRINOGEN LEVEL     
                   BETWEEN  GROUP  IB1  AND  GROUP  IB2 
Group 
Plasma Fibrinogen (mgs / dl) 
Mean SD 
Group IB1 315.9 34.7 
Group IB2 341.4 92.0 
‘p’ 0.3264 Not significant 
Plasma  fibrinogen  level  increased  in  patients  with  more  than  5  
years  duration  than  in  patients  with  less  than  5  years  duration. 
 
FIGURE 5: 
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TABLE 6 : COMPARISION  OF  PLASMA FIBRINOGEN LEVELS 
BETWEEN DIABETICS OF  LESS THAN 5  YEARS AND 
MORE THAN 5 YEARS  DURATION. 
Group 
Plasma Fibrinogen (mgs / dl) 
Mean SD 
GROUP  IA1+IB1 274.2 53.9 
GROUP  IA2+  IB2 278.1 104.4 
‘p’ <0.8534 Not Significant 
Plasma  fibrinogen  level  increased  in  patients  of   more  than  5  
years  duration  than  in  patients  of  less  than  5  years  duration,  but  
statistically  insignificant. 
 
FIGURE  6: 
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TABLE 7 : COMPARISION  OF  PLASMA FIBRINOGEN LEVEL  
BETWEEN   GROUP  IA  AND  GROUP  II 
GROUP 
Plasma Fibrinogen (mgs / dl) 
Mean SD 
GROUP  IA 217.4 52.0 
GROUP  II 160.3 49.7 
‘p’ <0.0001 Significant 
 
Statistically  significant  difference  in  plasma  fibrinogen  was  
observed  between  diabetes  with  HbA1c≤7%  and  in  control  group. 
 
FIGURE:7 
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TABLE 8:  COMPARISION  OF  PLASMA  FIBRINOGEN  
LEVELBETWEEN  GROUP  IB  AND  GROUP  II 
GROUP 
Plasma Fibrinogen (mgs / dl) 
Mean SD 
GROUP  IB 334.2 77.0 
GROUP  II 160.3 49.7 
‘p’ <0.0001 Significant 
 
Statistically significant  difference  in  plasma  fibrinogen  was  
observed  between  diabetes  with  HbA1c>7%  and  control  group. 
 
FIGURE : 8 
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TABLE 9:  COMPARISION  OF  PLASMA FIBRINOGEN LEVEL 
BETWEEN  GROUP  IA  AND  IB 
GROUP 
Plasma Fibrinogen (mgs / dl) 
Mean SD 
GROUP  IA 217 52.0 
GROUP  IB 
334.2 77.0 
‘p’ <0.0001 Significant 
Statistical  difference  in  plasma  fibrinogen  was  observed  between  
diabeticss  with  HbA1c≤7%  and  diabetes  with  HbA1c>7%. 
FIGURE :9 
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DISCUSSION 
Diabetes  mellitus  is  a  global  health  problem  and  is  
expected  to  affect  nearly  330  million  people  by  the  year  203062 . 
Cardiovascular  diseases  like  myocardial  infarction,  angina  are    
common  complications  of  diabetes  mellitus.  These  cardiovascular  
complications  accounting  for  nearly  75%  of  death  due  to  
thrombosis  in  diabetes72 .   
Traditional  risk  factors  like  systemic  hypertension,  smoking,  
obesity  and  dyslipidemia  have  not  been  fully  responsible  for  
cardiovascular  diseases  associated  morbidity  and  mortality  in  
diabetes 13.  
Altered  hemostasis  due  to  hypercoagulable  state  is  
implicated  as  an  important  risk  factor  responsible  for  
cardiovascular  complications  in  diabetes.  Among  the  hemostatic  
factors,  fibrinogen  has  been  involved  in  the  pathogenesis  of  
atherosclerosis  and  considered  as  an  independent  risk  factor  for  
cardiovascular  complications 66. 
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In  the  present  study,  75  type  II  diabetes  mellitus  patients  
were  taken  as  study  group  and  75  age  and  sex  matched  healthy  
individuals  taken  as  control  group.  This  study  shows  that,  mean 
plasma  fibrinogen  level  was  significantly  increased  in  the  study  
group  when  compared  to  control  group.  In  the  study  group  mean  
plasma  fibrinogen  level  was  276.6 ± 87.9 mg/dl,  whereas  in  the  
control  group  it  was  160.3 ± 47mg/dl. These  findings  were  
consistent  with  the  study  results  of  Archana  Sachin  Bembde68,  
Nizar  M.abderurahman  et  al67,  Taj  Muhammad  khan  et  al66,     
Ying  zhao  et  al71,  Ritu  Madan  et  al72, DR  Kafle  et  al69,            
Bruno  G  et  al65,  Venkataramana. G  et  al73.  
A  cross  sectional  study  done  among  1574  type  II  diabetes  
mellitus  patients  by  Bruno  G  et  al  observed  the  high  prevalence  
of  hyperfibrinogenemia  in  diabetes  and  fibrinogen  level  was  
significantly  associated  with  HbA1c  value 65. 
Nizar  and  Elshazali  described  that  mean  plasma  fibrinogen  
level  was  increased  significantly  in  Sudanese  diabetic  patients  but  
it  was  in  the  higher  limit  of  normal  range  (3.96±0.92)67. 
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Another  study  was  done  by  Ritu  Madan  et  al72  aimed  to  
know  the  coagulation  status  in  diabetic  patients. They  found  that,      
plasma  fibrinogen  levels  were  increased  in  diabetic  patients. Other  
coagulation  factors  like  factor  VII,  factor  VIII,  vWF,  factor  XI,  
factor  XII,  Kallikrein,  and  thrombin  antithrombin  complexes  are  
also  increased  in  diabetes.  They  said  that,  this  Procoagulant  state 
is  responsible  for  the  occurrence  of  macrovascular  as  well  as  
microvascular  complications  in  type  II  diabetes  mellitus. 
A  cross  sectional  study  done  by  Taj  Muhammad  Khan  et  
al to  know  the  association  between  plasma  fibrinogen  level  and  
diabetic  complications.  They  have  recruited  120  subjects.  Among  
them  40  subjects  were  controls,  40 subjects  were  diabetics   and  
40  subjects  were  diabetics  with  complications.  They  reported  that,  
plasma  fibrinogen  level  and  blood  viscosity  were  significantly  
high  in  diabetic  patients.  They  have  also  found  significant  
association  between  diabetic  complications  and  plasma  fibrinogen  
level66. 
A  case  control  study  done  on  100  diabetic  patients  by  A. 
S.  Bembde  aimed  to  know  the  level  of  plasma  fibrinogen  in  type  
II  diabetes  mellitus.  They  have  reported  that,  Plasma  fibrinogen  
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level  was  significantly  increased  in  type  II  diabetic  patients  when  
compared  to  Control  group.  They  said  that,  existence  of  
prothrombotic  state  in  diabetes  was  associated  with  increased  
plasma  fibrinogen  level68. 
Various  mechanisms  were  put  forward  regarding  increased  
plasma  fibrinogen  level  in  type  II  diabetes.  The  possible  
mechanisms  are, 
Low  grade  chronic  systemic  inflammation  present  in  type  II  
diabetes  is  associated  with  increased  synthesis  of  acute  phase  
reactant  proteins  by  the  liver77.   
In  an  experimental  study  done  in  rats  showed  that,  insulin  
deficiency  causes  decreased  albumin  mRNA  concentration  and  
decreased  albumin  synthesis,  whereas  fibrinogen  synthesis  was  not  
affected78.  Similar  study  done  in  human  diabetic  patients  reported  
that  insulin  deficiency  causes  50%  increase in  fibrinogen  synthesis  
and  29%  decrease  in  albumin  synthesis.  They  said  that,  this  
altered  protein  synthesis  is  due  to  insulin  deficiency  associated  
metabolic  stress  on  liver18.  This  increased  fibrinogen  production  
not  balanced  by  clearance  mechanism  leads  onto  elevated  
fibrinogen  in  the  plasma76. 
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Another  mechanism  is  that,  advanced  glycation  end  
products  produced  by  the  non  enzymatic  glycosylation  of  
intracellular  and  extracellular  proteins  induced  endothelial  
dysfunction   which   leads  onto  increased  amount  of  clotting  
factors  in  the  blood.  Activation  of  coagulation  pathway  results  in  
increased  production  of  thrombin  and  fibrin  degradation  products,  
which  in turn  enhances  fibrinogen  production  by  the  liver 71,72.  
In  the  present  study,  mean  plasma  fibrinogen  level  was  
increased  in  diabetic  patients  of  more  than  5  years  duration.  
Though  the  fibrinogen  level  increased,  it  was  statistically  
insignificant  and  indicates that duration  of  diabetes  have  a  less  
impact  on  fibrinogen  level. This  increased  level  of  fibrinogen  
might  be  due  to  pronounced  decrement  in  beta  cell  activity  with  
increase  in  insulin  resistance  in  diabetics  with  more  than  5  years  
duration 67. 
The  mean  plasma  fibrinogen  level  was  increased  
significantly  in  study  group  with  HbA1c  ≤ 7%  (271.4±52)  while  
compared  to  control  group  (160.3±49.7).  Mean  plasma  fibrinogen  
level  was  increased  significantly   in  study  group  with  HbA1c  > 
7%  (334.2±77)  while  compared  to  control  group  (160.3±49.7).  
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Mean  plasma  fibrinogen  level  was  increased  in  Patients  with  
HbA1c  > 7%  (334.2±77)  than  in  Patients  with  HbA1c  ≤ 7%  
(271.4±52)  and  these  results  were  statistically  significant.  These  
findings  were  consistent  with  Study  results  of  DR  Kafle  and  P  
Shrestha69,  Binayo  sapkota  et  al15,  Ying  Zao  et  al71,  
A.S.Bembde68,  Ogbera  and  Alfred79,  Nizar  and  Elshazali67. 
Plasma  fibrinogen  is  positively  correlated  with  glycosylated  
haemoglobin  (r=0.8166).  These  findings  were  consistent  with  the  
study  results  of  Ogbera  and  Alfred79,  Ying  Zao  et  al71,  Binayo  
sapkota  et  al15,  A.S.Bembde68,  Rodolfo-Guardado-Mendoza  et  al76,  
Antonio  ceriello et  al70 .   
The  possible  mechanisms  responsible  for  increased  
fibrinogen  level  in  patients  with  HbA1c>7%  are,  
In  patients  with  HbA1c>7%  (Poor  glycemic  control)  
lipoprotein  a  levels  are  suspected  to  be  increased.  This  LP(a)  
contains  protein  moiety  called  Apo(a).  This  Apo(a)  protein  have  
a  structural  similarity  with  plasminogen,  which  is  a  precursor  of  
plasmin  molecule  and  have  the  ability  to  bind  fibrin  molecule.   
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This  linkage  prevents  the  binding  of  plasminogen  and  tPA  
with  fibrin  and  by  which  Apo(a)   prevents  the  clot  lysis  and  
promotes  more  and  more  of  fibrin  deposition  at  the  site  of  vessel  
injury68.    
More  amount  of  glycosylated  fibrinogen  are  formed  during  
poor  glycemic  control.  Because  of  this  glycosylation,  nature  of 
fibrin  clot  structure  was  altered  and  it  contains  densely  packed  
thin  fibrin  fibers  with  reduced  pore  size.  These  glycosylated  
fibrinogen  are  more  resistant  to  plasmin  mediated  degradation  and  
also  promotes  more  amount  of  fibrin  deposistion68,62. 
This  increased  plasma  fibrinogen  involved  in  all  stages  of  
atherogenesis  and  considered  as  important  cardiovascular  risk  
factor.  Many  epidemiological  studies  have  found  positive  
association  between  plasma  fibrinogen  level  and  cardiovascular  
diseases.   
In  1987,  The  Framingham  study  reported that   there  was  
significant  association  present  between  plasma  fibrinogen  level  
and  coronary  artery  disease  and  also  added that   plasma  
fibrinogen  level  was   significantly  associated  with  other  
cardiovascular  risk  factors  like  systemic  hypertension,  obesity,  
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smoking  and  diabetes  mellitus.  This  study  considers  increased  
plasma  fibrinogen  level  as  a  predictor  of  cardiovascular  diseases  
and  they  have  recommended  that  plasma  fibrinogen  measurement  
should  be  included  in  the  cardiovascular  risk  profile38. 
Northwick  park  heart  study,  analysed  the  involvement  of  
thrombotic  factors  in  the  development  of  coronary  artery  diseases.  
They  had  investigated  1511  male  subjects  of  age  between  40-64  
years  and  found  the  association  between  Coronary  artery  disease  
and  factor  VII  activity,  fibrinogen 39. 
Cross  sectional  study  done  by  Luciana  &  his  co-workers  
showed  that,  plasma  fibrinogen  level  was  significantly  elevated  in  
patients  with  coronary  artery  disease  while  comparing  with  that  
of  normal  subjects.  Plasma  fibrinogen  level  was  also  well  
correlated  with  the  severity  of  coronary  artery  disease 15. 
Plasma  fibrinogen  level  was  significantly  increased  in  
diabetic  patients  with  complications  than  in  diabetic  patients  
without  complications66. 
Increased  plasma  fibrinogen  is  considered  as  independent  
cardiovascular  risk  factor.  In  a   cross  sectional  study  done  on  
type  II  diabetics  found  a  strong  association  between  silent  
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myocardial  ischemia  and  plasma  fibrinogen  level.  It  has  been  
suggested  that  plasma  fibrinogen  should  be  added  in  the  
cardiovascular  risk  profile  in  diabetic  patients76. 
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SUMMARY 
 Plasma  fibrinogen  level  was  compared  between  Type II   
diabetic patients   and  controls. 
 Plasma  fibrinogen  level  was  significantly  increased  in 
diabetic  patients  compared  to  controls. 
 Plasma  fibrinogen  level  was  increased  in diabetic  patients  
with  more  than  5  years  duration  of  diabetes. 
 Plasma  fibrinogen  level  was  significantly  increased  in  
patients  who  had  HbA1c > 7% . 
 Plasma  Fibrinogen  level  was  positively  correlated  with  
HbA1c  level. 
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CONCLUSION 
Fibrinogen  is  an  important  plasma  protein  involved  in  the  
blood  coagulation  mechanism.  Fibrinogen  is  converted  into  
insoluble  fibrin  in  the  injured  blood  vessel  and  forms  the  definite  
blood  clot,  which  seals  off   the  injured  vessel  wall  effectively.  
HbA1c  is  formed  by  binding  of  glucose  with  β  chain  of  
HbA  at  its  amino  terminal  valine.  The  life  span  of   RBC  is  
about  120 days,  during  which  haemoglobin  gets  attached  with 
glucose  molecule  to  form  glycosylated  haemoglobin. In diabetes 
Mellitus  patients  with  poor  glycemic  control, the quantity of 
glycosylated  haemoglobin  is  in  increased  amount  when compared 
to  patients  with  good  glycemic  control. 
In  the  present  study ,   increased  plasma  fibrinogen  level  
was  observed  in  diabetic  patients  having   HbA1c  of  more  than 
7%. It  could  be  due  to  insulin  deficiency  associated  metabolic  
stress,  advanced  glycation  end  products  mediated  endothelial  
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injury,  chronic  systemic  inflammation,  Apoprotein - a  and  
increased  amount  of  glycosylated  fibrinogen. 
This  elevated  plasma  fibrinogen  along  with  other  blood   
clotting  factors  produce  hypercoagulable  state  in  diabetes  mellitus.    
Increased  plasma  fibrinogen  alone  also  involved  in  all  stages of 
atherogenesis  and  considered  as  an  independent  cardiovascular  
risk  factor. 
The  present  study  also  observed  decreased  level  of  plasma  
fibrinogen  in  patients  with  HbA1c <7%    when  compared  to  
patients  with  HbA1c >7%.  It  states  that,  good  glycemic  control  in  
diabetic  patients  is  necessary  to  reduce  the  risk  of  cardiovascular  
complications.   
Hence  present  study  concludes  that,   measurement  of  
plasma  fibrinogen  is  considered  to  be  an  important  tool  to  assess  
cardiovascular  risk  in  type  II  diabetic  patients. 
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LIMITATIONS 
The  present  study  considers  plasma  fibrinogen  is  an  
important  tool  for  assessing   the  cardiovascular  risk  in  type  II  
diabetes  mellitus.   Large  sample  size  and  follow  up  studies  would  
be  of  great  value.   
Measurement  of  plasma  fibrinogen  along  with  other  
cardiovascular  risk  factors  in  diabetic  patients  will  be  needed  to  
demonstrate  the  excess  risk  of  cardiovascular  disease  associated    
mortality.  
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FUTURE STUDY PLAN 
The  current  study  is  of  public  health  importance  as  it  
suggests  that,  plasma  fibrinogen  should  be  added  in  the  screening  
tool  to  assess  cardiovascular  risk  status  in  type  II  diabetics. 
Further  followup  studies  are  needed  to  determine  whether  
good  glycemic  control  would  reverse  the  plasma  fibrinogen  level  
and  associated  cardiovascular  risk. 
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CONSENT FORM 
Dr.S.Bhuvaneswari, Post Graduate student in the 
Department of Physiology, Coimbatore Medical College is 
studying the “Correlation between   Plasma Fibrinogen Level 
and  Glycosylated  Hemoglobin in Type II Diabetes Mellitus  
Patients”.  Estimation of random  blood  sugar, plasma 
fibrinogen, HbA1c  were explained to me clearly. 
I hereby give my consent to participate in this study.The 
data obtained herein may be used for research and publication. 
 
Name  :  
 
Place  : 
 
Signature  : 
 
PROFORMA 
Name: 
Age :      
Sex: 
Occupation:                                       
Address:       Mobile No: 
Duration  of  Diabetes: 
History  of   Myocardial  infarction/Stroke/Neuropathy/Nephropathy/peripheral  
vascular  disease 
History  of  Systemic  hypertension/ chronic  Liver  disease/Recent  surgery. 
H/O  drug  intake 
Smoker/Non smoker   
Menstrual  History 
Height:   Weight:    BMI: 
Blood  Pressure:  mm/Hg         
Systemic  Examination 
Respiratorysytem   
Cardiovascular  system 
Central  nervous system 
 
Investigation: 
Plasma  fibrinogen (mg/dl) 
HbA1c (%) 
Random  blood  sugar  (mg/dl) 
  
 
 
 
 
 
 
 
 
 
 
 
 
MASTER  CHART 
 
age sex BP weight height BMI
1 46 F 112/80 55 148 25 <5 5.8 218
2 41 M 124/76 62 155 25.8 <5 5.4 173
3 55 F 104/70 53 145 25.2 <5 6.9 210
4 47 F 114/70 53 146 25.2 <5 6.5 268
5 40 F 102/74 55 152 23.9 <5 5.4 168
6 45 F 116/72 56 148 25.5 <5 5.9 235
7 40 F 120/80 60 155 25 <5 5.9 200
8 45 F 96/70 48 156 19.7 <5 6.5 274
9 40 F 104/72 55 146 26.1 <5 6.0 256
10 46 M 120/80 72 170 24.9 <5 6.5 268
11 55 M 114/72 65 160 25.3 <5 6.9 290
12 42 F 110/70 59 156 24.2 <5 6.2 239
13 60 M 110/80 70 163 26.3 <5 6.9 225
14 52 M 112/72 70 162 26.3 <5 6 242
15 44 M 108/78 70 172 23.66 <5 6.4 263
16 52 F 102/74 52 150 23 >5 5.2 112
17 51 M 110/70 63 156 25.8 >5 6.5 283
18 56 M 120/78 68 162 25.9 >5 6.7 265
19 55 M 116/72 65 161 25 >5 5.8 198
20 47 F 106/70 52 156 21.3 >5 5.9 147
21 42 F 100/70 52 153 22.2 >5 5.9 159
22 45 F 98/72 68 162 25.9 >5 6.5 290
23 54 F 112/72 52 146 24.3 >5 6.4 235
24 44 M 114/76 59 160 23 >5 6.8 269
25 50 M 102/74 58 156 23.8 >5 6.1 260
26 53 F 120/80 57 150 25.3 >5 6.4 253
27 45 M 116/70 69 163 25.9 >5 6.7 272
28 60 F 106/70 58 155 24 >5 5.8 142
29 42 M 98/70 67 168 23.7 >5 6.7 240
30 53 M 110/80 72 163 27.1 >5 6.1 153
31 58 M 112/70 65 158 26 >5 5.9 193
32 43 F 120/82 56 150 24.8 >5 6.3 156
33 49 F 114/68 48 150 21.3 >5 6.8 174
34 45 M 106/70 63 156 25.8 >5 7 259
35 52 F 112/70 59 152 25.5 >5 6.2 145
36 47 M 108/70 67 160 26 >5 6.5 124
37 40 F 110/74 58 155 24 >5 5.9 186
HbA1c in %
 fibrinogen 
in mgs/dl
S.No
MASTER  CHART  I - STUDY  GROUP
Diabetics with HbA1c  <7%
BP - BLOOD PRESSURE RBS - RANDOM BLOOD SUGAR
BMI - BODY MASS INDEX HbA1c - HEMOGLOBIN A1c
duration of 
diabetes
age sex BP weight height BMI
38 53 F 120/80 55 152 23.8 <5 8.1 320
39 47 M 120/80 62 156 25.4 <5 7.3 272
40 45 M 112/74 69 162 26.2 <5 10.6 360
41 57 F 110/70 65 160 25.3 <5 8.4 326
42 43 M 126/70 70 163 26.35 <5 7.8 312
43 55 F 106/70 60 158 24 <5 12.6 280
44 58 F 110/80 63 153 26.9 <5 10.7 372
45 46 M 116/70 68 158 27.2 <5 7.8 290
46 49 F 108/74 58 146 27.2 <5 9.9 315
47 45 M 114/70 65 163 24.4 <5 10.0 354
48 44 F 114/64 58 151 25.4 <5 8.5 320
49 53 M 122/76 73 168 25.8 <5 7.4 263
50 55 F 124/70 54 158 21.6 <5 10.8 353
51 41 M 110/74 62 157 25 <5 8.0 285
52 43 M 110/70 59 162 22.4 >5 13.0 386
53 46 M 116/70 66 160 25.7 >5 7.7 265
54 49 F 120/76 58 155 24.1 >5 8.1 298
55 53 M 110/80 68 162 25.9 >5 12.1 375
56 40 F 106/70 63 161 24.3 >5 8.5 270
57 46 M 112/70 68 170 23.5 >5 11.4 295
58 54 M 116/74 68 158 27.2 >5 11.6 322
59 50 M 110/78 63 165 23 >5 13.3 430
60 52 F 106/72 65 153 26.9 >5 13.5 520
61 47 M 108/74 62 155 25.8 >5 8.4 245
62 41 M 110/80 70 165 25.7 >5 12.9 310
63 60 F 120/76 60 158 24 >5 10.7 339
64 49 F 120/70 65 155 27 >5 10.2 337
65 45 F 114/72 63 157 25.5 >5 9.3 212
66 48 F 124/80 60 151 26.3 >5 10.1 305
67 44 M 106/76 68 165 24.9 >5 8.2 295
68 49 F 104/70 60 153 25.6 >5 7.8 247
69 52 F 112/70 57 158 22.8 >5 13.0 552
70 56 F 116/70 63 156 25.8 >5 13.5 568
71 43 M 112/70 65 167 23.3 >5 11.5 365
72 56 M 108/76 68 162 25.9 >5 12.5 370
73 51 F 120/80 59 153 25.2 >5 8.5 320
74 42 F 120/80 54 150 24 >5 8.5 345
75 46 F 122/76 60 152 25.9 >5 11.6 305
S.No
Diabetics with HbA1c  >7% duration of 
diabetes
HbA1c in %
 fibrinogen 
in mgs/dl
BMI - BODY MASS INDEX HbA1c - HEMOGLOBIN A1c
BP - BLOOD PRESSURE RBS - RANDOM BLOOD SUGAR
MASTER  CHART  2 - STUDY  GROUP
S.No Age Sex BP Weight Height BMI RBS  fibrinogen 
76 40 M 106/70 62 158 27.5 112 167
77 46 M 110/70 70 164 28 124 93
78 52 M 120/80 65 162 25 140 96
79 43 F 114/74 55 150 24 98 200
80 46 F 112/72 48 152 21.3 117 135
81 48 F 114/80 55 148 24 114 139
82 42 F 116/70 57 150 25.3 136 105
83 51 M 114/80 65 168 23 145 200
84 55 F 120/76 64 162 25 116 142
85 55 F 114/70 60 156 26.6 124 102
86 54 F 120/80 59 160 23 116 114
87 44 F 124/80 58 156 24 118 118
88 42 M 116/80 57 150 25.3 136 78
89 41 F 114/74 69 163 26.9 122 112
90 53 F 112/80 55 155 24.4 124 142
91 56 M 116/80 60 168 21.4 102 133
92 55 M 112/80 72 163 28 96 176
93 51 F 114/74 65 158 26 120 149
94 43 M 116/70 56 150 24.8 115 195
95 42 M 120/82 48 150 21.3 106 147
96 46 M 124/80 63 156 26.2 102 112
97 41 F 120/80 59 152 26.2 116 128
98 45 M 122/80 67 155 27.9 118 126
100 49 M 124/80 58 155 25.7 94 145
101 52 M 112/70 55 152 23.9 86 194
103 53 F 120/76 62 156 25.8 110 173
104 55 F 126/80 69 162 27.6 100 187
105 41 F 120/80 65 160 25.3 98 108
106 43 F 112/70 70 163 27.3 126 153
107 46 M 114/74 65 158 25.39 132 104
108 49 M 112/72 63 153 28 145 159
109 53 F 114/80 68 156 29.56 112 118
110 40 M 116/70 52 146 24.7 124 91
111 46 F 114/80 65 157 25 140 172
112 54 M 120/76 58 151 25.7 98 121
113 50 M 110/80 70 168 25 117 93
114 52 M 120/76 54 158 21 114 124
115 47 F 120/70 62 157 24.2 136 186
116 41 F 114/72 57 162 22.6 145 148
117 60 M 124/80 66 160 25.7 116 79
118 49 F 106/76 58 155 24 124 212
119 45 M 104/70 68 162 26.5 116 189
120 48 F 112/70 55 148 25 118 232
121 44 M 116/70 62 155 25.8 136 220
MASTER CHART 3 - CONTROL GROUP
122 46 M 112/70 56 145 25.4 122 270
123 41 M 108/76 53 146 23.5 106 195
124 55 F 120/80 55 152 24.4 102 215
125 47 F 120/80 58 148 25.7 116 125
126 40 M 122/76 60 155 25 118 160
127 45 F 110/74 52 156 21.6 94 135
128 40 M 110/70 55 146 25 86 105
129 45 F 116/70 72 170 24.8 110 226
130 65 M 120/76 65 160 25.3 100 163
131 46 M 110/80 59 156 24.5 98 145
132 55 F 106/70 70 158 29.1 126 176
133 64 F 112/70 73 162 32.4 132 153
134 60 M 116/74 55 148 24.4 145 155
135 52 F 110/78 62 155 25.8 112 98
136 44 M 106/72 56 145 25.4 124 168
137 52 M 110/74 53 146 24 140 260
138 51 F 110/70 55 152 24.4 106 114
139 56 M 116/70 58 148 26.3 102 126
140 55 F 120/76 60 155 25 116 236
141 47 F 110/80 52 156 21.6 118 212
142 42 M 106/70 55 146 25 94 272
143 45 F 112/70 72 170 24.8 86 182
144 54 M 116/74 65 160 25.3 110 248
145 44 F 110/78 59 156 24.5 100 232
146 60 M 106/70 70 158 29 98 250
147 51 F 110/74 73 162 28.5 126 230
148 42 M 110/70 55 148 25 132 125
149 40 M 116/70 62 155 25.8 145 195
150 40 M 120/76 56 145 24.4 112 215
BMI - BODY MASS INDEX
BP - BLOOD PRESSURE
RBS - RANDOM BLOOD SUGAR
